[go: up one dir, main page]

WO2023001300A1 - 艾日布林衍生物的药物偶联物 - Google Patents

艾日布林衍生物的药物偶联物 Download PDF

Info

Publication number
WO2023001300A1
WO2023001300A1 PCT/CN2022/107479 CN2022107479W WO2023001300A1 WO 2023001300 A1 WO2023001300 A1 WO 2023001300A1 CN 2022107479 W CN2022107479 W CN 2022107479W WO 2023001300 A1 WO2023001300 A1 WO 2023001300A1
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
cancer
drug conjugate
peg
conjugate according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2022/107479
Other languages
English (en)
French (fr)
Inventor
孙星
杨昌永
梁金栋
廖成
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Hengrui Pharmaceutical Co Ltd
Jiangsu Hengrui Pharmaceutical Co Ltd
Shanghai Shengdi Pharmaceutical Co Ltd
Shanghai Senhui Medicine Co Ltd
Original Assignee
Shanghai Hengrui Pharmaceutical Co Ltd
Jiangsu Hengrui Pharmaceutical Co Ltd
Shanghai Shengdi Pharmaceutical Co Ltd
Shanghai Senhui Medicine Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Hengrui Pharmaceutical Co Ltd, Jiangsu Hengrui Pharmaceutical Co Ltd, Shanghai Shengdi Pharmaceutical Co Ltd, Shanghai Senhui Medicine Co Ltd filed Critical Shanghai Hengrui Pharmaceutical Co Ltd
Priority to EP22845463.3A priority Critical patent/EP4374879A1/en
Priority to KR1020247004483A priority patent/KR20240037267A/ko
Priority to JP2024502528A priority patent/JP2024525854A/ja
Priority to CN202280041358.1A priority patent/CN117460540A/zh
Priority to CA3225975A priority patent/CA3225975A1/en
Priority to US18/290,721 priority patent/US20240382607A1/en
Priority to MX2024000893A priority patent/MX2024000893A/es
Priority to AU2022316425A priority patent/AU2022316425A1/en
Publication of WO2023001300A1 publication Critical patent/WO2023001300A1/zh
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Definitions

  • the present disclosure relates to drug conjugates of eribulin derivatives.
  • Antibody drug conjugates link monoclonal antibodies or antibody fragments to biologically active drugs through stable chemical linker compounds, making full use of the specificity and The high efficiency of the drug avoids defects such as low curative effect of the former and excessive side effects of the latter. This means that, compared with traditional chemotherapy drugs in the past, antibody drug conjugates can precisely bind tumor cells and reduce the impact on normal cells.
  • the first antibody-drug conjugate Mylotarg (gemtuzumab ozogamicin, Wyeth Pharmaceutical Co., Ltd.) was approved by the US FDA for the treatment of acute myeloid leukemia, and entered the clinical stage.
  • There are a total of 164 ADC drugs, most of which (n 100) are in the first clinical phase, 46 are in the second clinical phase, 7 are in the third clinical phase, and 3 are BLA-applied drugs.
  • Representative drugs of the third generation are Polatuzumab vedotin (trade name, Polivy, approved for marketing in June 2019) jointly developed by Genentech and Genetics, and Enfortumab vedotin jointly developed by Agensys (a subsidiary of Astellas) and Seattle Genetics (trade name, Padcev, December 2019) and Fam-trastuzumab deruxtecan (trade name, Enhertu) developed by Daiichi Sankyo.
  • Microtubules are powerful, filamentous cytoskeletal proteins associated with a variety of cellular functions including intracellular migration and transport, cell signaling, and maintenance of cell shape. Microtubules also play a key role in mitotic cell division by forming the mitotic spindle required for the division of chromosomes into two daughter cells.
  • the biological function of microtubules in all cells is largely regulated by their polymerization kinetics through the reversible, noncovalent addition of ⁇ and ⁇ tubulin dimers to the ends of microtubules. This kinetic behavior and the resulting control of microtubule length are integral to the proper function of the mitotic spindle.
  • tubulin inhibitors and other microtubule-targeting agents are expected to become a class of drugs for the treatment of cancer.
  • ADC antibody-drug conjugate
  • Ab is a HER2 antibody or an antigen-binding fragment thereof that binds to domain II of HER2,
  • L is a linker covalently linking Ab to D
  • k is 1 to 20 (including 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 , 16, 17, 18, 19, 20 or any value between any two values)
  • k in the antibody-drug conjugate Ab-(LD) k is selected from 1 to 10, and may be an integer or a decimal.
  • the linker is stable extracellularly such that the ADC remains intact when present in the extracellular environment, but is capable of cleavage when internalized in a cell, eg, a cancer cell.
  • the ADC enters a cell expressing an antigen specific for the antibody portion of the ADC
  • the Eribulin Derivative drug moiety is cleaved from the antibody portion, and the cleavage releases the unmodified form of the Eribulin Derivative .
  • the cleavable moiety in the linker is a cleavable peptide moiety.
  • ADCs comprising a cleavable peptide moiety exhibit lower levels of aggregation, improved antibody:drug ratios, increased targeted killing of cancer cells, reduced non- Off-target killing of cancer cells, and/or high drug load.
  • addition of a cleavable moiety increases cytotoxicity and/or potency relative to a non-cleavable linker.
  • the cleavable peptide moiety is capable of being cleaved by an enzyme, and the linker is one that is cleavable by an enzyme.
  • the enzyme is a cathepsin and the linker is a linker that the cathepsin is capable of cleaving.
  • an enzyme-cleavable linker eg, a cathepsin-cleavable linker
  • the linker comprises an amino acid unit, preferably comprising 2 to 7 amino acids selected from the group consisting of phenylalanine, glycine, valine, lysine, citrulline, serine, glutamic acid, Peptide residues composed of amino acids of aspartic acid, more preferably valine-citrulline (Val-Cit), alanine-alanine-asparagine (Ala-Ala-Asn), glycine-glycine- Lysine (Gly-Gly-lys), Valine-Lysine (Val-lys), Valine-Alanine (Val-Ala), Valine-Phenylalanine (Val-Phe) Or glycine-glycine-phenylalanine-glycine (Gly-Gly-Phe-Gly).
  • linkers of the disclosure comprising amino acid units are selected from:
  • the amino acid unit comprises valine-citrulline (Val-Cit).
  • ADCs comprising Val-Cit exhibit increased stability, reduced off-target cell killing, increased on-target cell killing, lower Aggregation levels, and/or higher drug loading.
  • some embodiments provide linkers comprising a cleavable sulfonamide moiety that are capable of being cleaved under reducing conditions.
  • the linker comprises a cleavable disulfide moiety that is capable of being cleaved under reducing conditions.
  • the linker in the antibody conjugate of the present disclosure comprises at least one spacer unit linking the eribulin derivative D to the cleavable moiety.
  • the linker comprises a spacer unit attached to D.
  • the spacer unit comprises p-aminobenzyloxycarbonyl (pAB),
  • the spacer unit comprises:
  • Z 1 to Z 4 are each independently selected from carbon atoms or nitrogen atoms;
  • R 4 is selected from alkyl, cycloalkyl, aryl and heteroaryl, and said alkyl, cycloalkyl, aryl and heteroaryl Aryl groups are each independently optionally selected from the group consisting of alkyl, alkoxy, halogen, amino, cyano, nitro, hydroxy, hydroxyalkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl One or more substituents are substituted;
  • R 1 and R 2 are each independently selected from hydrogen, C 1-6 alkyl, haloalkyl or C 3-6 cycloalkyl, preferably hydrogen; or, R 1 and R 2 are compatible with The connected carbon atoms together form C 3-6 cycloalkyl;
  • X is selected from -O- or -NH-;
  • L is selected from integers between 1-4;
  • Q is VE
  • VE provides a glycosidic bond that can be cleaved by glycosidase located in the cell
  • E is selected from -O-, -S- or -NR 3 -
  • R 3 is selected from hydrogen or methyl
  • V is selected from since wherein R 5 is selected from —COOH or CH 2 OH. In some embodiments, V is selected from -COOH.
  • the spacer unit comprises:
  • L-D in the antibody conjugate (ADC) of the present disclosure is a chemical moiety represented by the formula:
  • Str is the stretch base unit covalently linked to Ab
  • Pep is selected from amino acid units.
  • Str in the ADC is selected from the chemical moieties represented by the formula:
  • R 6 is selected from -WC(O)-, -C(O)-WC(O)-, (CH 2 CH 2 O) p1 C(O)-, (CH 2 CH 2 O) p1 CH 2 C( O)-, (CH 2 CH 2 O) p1 CH 2 CH 2 C(O)-, wherein W is selected from C 1-8 alkylene, C 1-8 alkylene-cycloalkyl or 1 to 8 A straight-chain heteroalkylene group of atoms, said heteroalkylene group comprising 1 to 3 heteroatoms selected from N, O or S, wherein said C 1-8 alkylene, C 1-8 alkylene - Cycloalkyl and linear heteroalkylene are each independently optionally further substituted by one or more of halogen, hydroxy, cyano, amino, alkyl, chloroalkyl, alkoxy and cycloalkyl base replaced;
  • L 1 is selected from -NR 7 (CH 2 CH 2 O) p1 CH 2 CH 2 C(O)-, -NR 7 (CH 2 CH 2 O) p1 CH 2 C(O)-, -S(CH 2 ) p1 C(O)-, -(CH 2 ) p1 C(O)- or a chemical bond, preferably a chemical bond; wherein, p1 is an integer from 1 to 20 , and R is selected from a hydrogen atom, an alkyl group, a haloalkyl group and a hydroxyalkyl group .
  • a linker can comprise at least one polyethylene glycol (PEG) moiety.
  • PEG polyethylene glycol
  • the PEG moiety may for example contain -(PEG) p1- , where p1 is an integer from 1 to 20, for example (PEG) 2 ; (PEG) 4 ; (PEG) 5 .
  • the spacer unit in the linker comprises (PEG) 2 .
  • ADCs comprising shorter spacer units (eg, (PEG) 8 ) exhibit lower Aggregation levels and/or higher drug loading.
  • R 7 in the antibody-drug conjugate is selected from C 1-6 alkylene C(O)-, -(CH 2 -CH 2 O) 2 C(O)-, -( CH 2 -CH 2 O) 2 CH 2 C(O)-, -(CH 2 -CH 2 O) 2 CH 2 CH 2 C(O)-, -(CH 2 -CH 2 O) 3 C(O) - and -( CH2 - CH2O) 4C (O)-.
  • the linker L in the antibody-drug conjugate comprises: maleimide-(PEG) 2 -Val-Cit, maleimide-(PEG) 6 - Val-Cit, Maleimide-(PEG) 8 -Val-Cit, Maleimide-(PEG) 4 -CH 2 CH 2 C(O)-Val-lys, Maleene Imide-(CH 2 ) 5 -Val-Cit, Maleimide-(CH 2 ) 5 -Val-lys, Maleimide-(CH 2 ) 5 -Gly-Gly -Phe-Gly, maleimide-(PEG) 2 -Ala-Ala-Asn, maleimide-(PEG) 6 -Ala-Ala-Asn, maleimide -(PEG) 8 -Ala-Ala-Asn, maleimide-(PEG) 4 -triazole-(PEG) 3 -sulfonamide, maleimide-(PEG) 2- CH
  • Str in the antibody-drug conjugate is selected from a chemical moiety represented by the following formula:
  • R 8 is selected from C 1-10 alkylene, C 2-10 alkenyl, (C 1-10 alkylene) O-, N(R d )-(C 2-6 alkylene)-N( R d ) and N(R d )-(C 2-6 alkylene); and each R d is independently H or C 1 -C 6 alkyl.
  • the antibody-drug conjugate is represented by the following formula:
  • k is selected from 1 to 10, and can be an integer or a decimal; p2 is selected from an integer between 1-6;
  • k is selected from 1 to 10, and can be an integer or a decimal; p2 is selected from an integer between 1-6;
  • k is selected from 1 to 10, and can be an integer or a decimal; p2 is selected from an integer between 1-6.
  • antibody-drug conjugate (ADC) of the present disclosure is selected from:
  • k is selected from 1 to 10, and may be an integer or a decimal.
  • variable region sequences of the heavy and light chains of the heavy and light chains of the HER2 antibody or antigen-binding fragment thereof bound to the domain II of HER2 are as follows:
  • trastuzumab The following is the sequence of trastuzumab:
  • k in the antibody conjugate of the present disclosure is selected from 2.0 to 2.5, including 2.0, 2.1, 2.2, 2.3, 2.4, 2.5 or any value in between.
  • k in the antibody conjugate of the present disclosure is selected from 2.5 to 3.5, including 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.1, 3.2, 3.3, 3.4, 3.6, 3.7, 3.8, 3.9, 4.0 or any value between two numbers.
  • k in the antibody conjugate of the present disclosure is selected from 3.5 to 5.0, including 3.5, 3.6, 3.7, 3.8, 3.9, 4.0, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5.0 or any value in between.
  • the present disclosure also provides isotopic substitutions of the foregoing antibody-conjugates.
  • the isotope substitution is deuterium atom substitution.
  • the present disclosure also provides a pharmaceutical composition, which contains a therapeutically effective amount of the aforementioned antibody-drug conjugate, or its isotope substitution, and a pharmaceutically acceptable carrier, diluent or excipient.
  • the unit dose of the pharmaceutical composition is 0.001 mg-1000 mg.
  • the pharmaceutical composition contains 0.01-99.99% of the aforementioned antibody-drug conjugate, or an isotope substitute thereof. In certain embodiments, the pharmaceutical composition contains 0.1-99.9% of the aforementioned antibody-drug conjugate, or an isotope substitute thereof. In some embodiments, the pharmaceutical composition contains 0.5%-99.5% of the aforementioned antibody-drug conjugate, or its isotope substitute. In certain embodiments, the pharmaceutical composition contains 1%-99% of the aforementioned antibody-drug conjugate, or its isotope substitute. In some embodiments, the pharmaceutical composition contains 2%-98% of the aforementioned antibody-drug conjugate, or its isotope substitute.
  • the pharmaceutical composition contains 0.01%-99.99% of pharmaceutically acceptable excipients based on the total weight of the composition. In certain embodiments, the pharmaceutical composition contains 0.1%-99.9% of pharmaceutically acceptable excipients. In certain embodiments, the pharmaceutical composition contains 0.5%-99.5% of pharmaceutically acceptable excipients. In certain embodiments, the pharmaceutical composition contains 1%-99% of pharmaceutically acceptable excipients. In certain embodiments, the pharmaceutical composition contains 2%-98% of pharmaceutically acceptable excipients.
  • the present disclosure also provides a use of the aforementioned antibody-drug conjugate or the aforementioned pharmaceutical composition in the preparation of a drug for treating or preventing tumors.
  • the tumor is a cancer associated with domain II expression of HER2.
  • the present disclosure also provides a use of the aforementioned antibody-drug conjugate or the aforementioned pharmaceutical composition in preparing a drug for treating and/or preventing cancer.
  • the cancer is selected from the group consisting of breast cancer, ovarian cancer, cervical cancer, uterine cancer, prostate cancer, kidney cancer, urethral cancer, bladder cancer, liver cancer, gastric cancer, endometrial cancer, salivary gland cancer, esophageal cancer, Melanoma, glioma, neuroblastoma, sarcoma, lung cancer, colon cancer, rectal cancer, colorectal cancer, leukemia, bone cancer, skin cancer, thyroid cancer, pancreatic cancer, and lymphoma.
  • the present disclosure also provides a method for treating or preventing a cancer patient related to the expression of domain II of HER2, by administering to the patient a therapeutically effective amount of the aforementioned antibody-drug conjugate, or an isotope substitute thereof, or The foregoing pharmaceutical composition.
  • the present disclosure also provides the aforementioned antibody-drug conjugates, or isotope substitutions thereof, or the aforementioned pharmaceutical compositions for treating or preventing cancers associated with the expression of Domain II of HER2.
  • the active compound may be presented in a form suitable for administration by any suitable route, preferably in unit dosage form, or in such a form that the patient can self-administer a single dose.
  • the unit dosage form of a compound or composition of the present invention may be expressed as a tablet, capsule, cachet, bottle, powder, granule, lozenge, suppository, reconstitution powder or liquid preparation.
  • Compounds of the present disclosure may exist in particular geometric or stereoisomeric forms. This disclosure contemplates all such compounds, including cis and trans isomers, (-)- and (+)-enantiomers, (R)- and (S)-enantiomers, diastereomers isomers, (D)-isomers, (L)-isomers, and their racemic and other mixtures, such as enantiomerically or diastereomerically enriched mixtures, all of which are within the scope of this disclosure. Additional asymmetric carbon atoms may be present in substituents such as alkyl groups. All such isomers, as well as mixtures thereof, are included within the scope of this disclosure. Compounds of the present disclosure containing asymmetric carbon atoms can be isolated in optically pure or racemic forms. Optically pure forms can be resolved from racemic mixtures or synthesized by using chiral starting materials or reagents.
  • Optically active (R)- and (S)-isomers as well as D and L-isomers can be prepared by chiral synthesis or chiral reagents or other conventional techniques. If one enantiomer of a compound of the present disclosure is desired, it can be prepared by asymmetric synthesis or derivatization with chiral auxiliary agents, wherein the resulting diastereomeric mixture is separated and the auxiliary group is cleaved to provide pure desired enantiomer.
  • a diastereoisomeric salt is formed with an appropriate optically active acid or base, and then a diastereomeric salt is formed by a conventional method known in the art. Diastereomeric resolution is performed and the pure enantiomers are recovered. Furthermore, the separation of enantiomers and diastereomers is usually accomplished by the use of chromatography using chiral stationary phases, optionally in combination with chemical derivatization methods (e.g. amines to amino groups formate).
  • the bond Indicates unassigned configuration, i.e. if chiral isomers exist in the chemical structure, the bond can be or both Two configurations.
  • key Denotes unassigned configuration, including cis (E) or trans (Z) configuration. or as described in this disclosure refers to a double bond, and the bonded structure can be "cis-isomer” or “trans-isomer” or "a mixture of cis-isomer and trans-isomer in any ratio",
  • formula E represents E-1, formula E-2 or a mixture of the two in any ratio:
  • the bond If the configuration is not specified, it can be the Z configuration or the E configuration, or both configurations.
  • tautomer or "tautomeric form” refers to structural isomers of different energies that can interconvert via a low energy barrier.
  • proton tautomers also known as prototropic tautomers
  • lactam-lactim isomerization
  • An example of a lactam-lactim equilibrium is between A and B as shown below.
  • the present disclosure also includes certain isotopically labeled compounds of the disclosure that are identical to those described herein, but wherein one or more atoms are replaced by an atom of an atomic mass or mass number different from that normally found in nature.
  • isotopes that can be incorporated into compounds of the present disclosure include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, iodine, and chlorine, such as 2 H, 3 H, 11 C, 13 C, 14 C, 13 N, 15 N, 15 O, 17 O, 18 O, 31 P, 32 P, 35 S, 18 F, 123 I, 125 I and 36 Cl, etc.
  • deuterium when a position is specifically designated as deuterium (D), the position is understood to have an abundance of deuterium (i.e., at least 10 % deuterium incorporation).
  • exemplary compounds having a natural abundance greater than deuterium can be at least 1000 times more abundant deuterium, at least 2000 times more abundant deuterium, at least 3000 times more abundant deuterium, at least 4000 times more abundant deuterium, at least 5000 times more abundant deuterium, at least 6000 times more abundant deuterium, or more abundant deuterium.
  • the present disclosure also includes various deuterated forms of compounds of formula (I). Each available hydrogen atom attached to a carbon atom can be independently replaced by a deuterium atom.
  • deuterated starting materials can be used in the preparation of deuterated forms of compounds of formula (I), or they can be synthesized using conventional techniques using deuterated reagents, including but not limited to deuterated borane, trideuterated Borane tetrahydrofuran solution, deuterated lithium aluminum hydride, deuterated ethyl iodide and deuterated methyl iodide, etc.
  • C 1-6 alkyl optionally substituted by halogen or cyano means that halogen or cyano may but not necessarily exist, and this description includes the case where the alkyl is substituted by halogen or cyano and the alkyl is not substituted by halogen And the case of cyano substitution.
  • “Pharmaceutical composition” means a mixture containing one or more compounds described herein, or a physiologically acceptable salt or prodrug thereof, and other chemical components, as well as other components such as physiologically acceptable carriers and excipients. agent.
  • the purpose of the pharmaceutical composition is to promote the administration to the organism, facilitate the absorption of the active ingredient and thus exert biological activity.
  • “Pharmaceutically acceptable excipients” include, but are not limited to, any adjuvants, carriers, excipients, glidants, sweeteners, diluents, agent, preservative, dye/colorant, flavor enhancer, surfactant, wetting agent, dispersant, suspending agent, stabilizer, isotonic agent, solvent or emulsifier.
  • an “effective amount” or “therapeutically effective amount” as used in the present disclosure includes an amount sufficient to ameliorate or prevent a symptom or condition of a medical condition.
  • An effective amount also means an amount sufficient to allow or facilitate diagnosis.
  • Effective amounts for a particular patient or veterinary subject may vary depending on factors such as the condition being treated, the general health of the patient, the method, route and dosage of administration, and the severity of side effects.
  • An effective amount may be the maximum dose or dosing regimen that avoids significant side effects or toxic effects.
  • drug refers to cytotoxic drugs or immunomodulators.
  • Cytotoxic drugs can have strong chemical molecules in tumor cells that disrupt their normal growth. In principle, cytotoxic drugs can kill tumor cells at a sufficiently high concentration, but due to lack of specificity, they can also cause apoptosis of normal cells while killing tumor cells, resulting in serious side effects.
  • the term includes toxins, such as small molecule toxins or enzymatically active toxins of bacterial, fungal, plant or animal origin, radioactive isotopes (e.g.
  • Immunomodulators are inhibitors of immune checkpoint molecules.
  • linker refers to a chemical structural fragment or bond that is connected to a ligand at one end and a drug at the other end, and can also be connected after other linkers. Then connect with the drug.
  • a joint may comprise one or more joint components.
  • exemplary linker building blocks include 6-maleimidocaproyl (MC), maleimidopropionyl (MP), valine-citrulline (Val-Cit or vc), alanine-phenyl Alanine (ala-phe), p-aminobenzyloxycarbonyl (PAB), and those derived from coupling with linker reagents: N-succinimidyl 4-(2-pyridylthio)pentanoate ( SPP), N-succinimidyl 4-(N-maleimidomethyl)cyclohexane-1 carboxylate (SMCC, also referred to herein as MCC) and N-succinimidyl (4 -iodo-acetyl)aminobenzoate (SIAB).
  • MC 6-maleimidocaproyl
  • MP maleimidopropionyl
  • Vcit valine-citrulline
  • Linkers can include Stretch units, Spacer units, Amino Acid units and Stretcher units. It can be synthesized by methods known in the art, such as described in US2005-0238649A1.
  • the linker can be a "cleavable linker" that facilitates release of the drug in the cell.
  • acid-labile e.g., hydrazone
  • protease-sensitive e.g., peptidase-sensitive
  • photolabile, dimethyl, or disulfide-containing linkers can be used (Chari et al., Cancer Research 52:127-131 (1992); US Patent No. 5,208,020).
  • stretch unit refers to a chemical structural fragment that is covalently linked to the antibody through a carbon atom at one end and to an amino acid unit, disulfide moiety, sulfonamide moiety, or non-peptidic chemical moiety at the other end.
  • spacer unit is a bifunctional compound structural fragment that can be used to couple amino acid units and cytotoxic drugs to form antibody-drug conjugates. This coupling method can selectively link cytotoxic drugs to amino acid units superior.
  • amino acid refers to an organic compound containing an amino group and a carboxyl group in the molecular structure, and both the amino group and the carboxyl group are directly connected to the -CH- structure.
  • the general formula is H 2 NCHRCOOH, R is H, substituted or unsubstituted alkyl, etc. According to the position of the amino group connected to the carbon atom in the carboxylic acid, it can be divided into ⁇ , ⁇ , ⁇ , ⁇ , ⁇ ...-amino acids.
  • amino acids that make up natural proteins have their specific structural characteristics, that is, their amino groups are directly connected to the ⁇ -carbon atom, that is, ⁇ -amino acids, including glycine (Glycine), alanine (Alanine), valine (Valine), Leucine, Isoleucine, Phenylalanine, Tryptophan, Tyrosine, Aspartic acid, Histidine, Asparagine, Glutamic acid, Lysine, Glutamine, Methionine, Arginine , Serine, Threonine, Cysteine, Proline, etc. Unnatural amino acids such as citrulline.
  • the spacer unit in the present disclosure is PAB, the structure is like a p-aminobenzyloxycarbonyl segment, and its structure is shown in formula (VI), connected to D,
  • Joint components include but are not limited to:
  • MC 6-maleimidocaproyl
  • Val-Cit or "vc” valine-citrulline (an exemplary dipeptide in a protease cleavable linker)
  • Me-Val-Cit N-methyl-valine-citrulline (wherein the linker peptide bond has been modified to prevent its cleavage by cathepsin B)
  • MC(PEG) 6 -OH maleimidocaproyl-polyethylene glycol (can be attached to antibody cysteine)
  • SPDP N-succinimidyl 3-(2-pyridyldithio)propionate
  • SMCC succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate
  • PBS Phosphate Buffered Saline.
  • antibody-drug conjugate means that a ligand is linked to a biologically active drug through a stable linker unit.
  • antibody drug conjugate refers to linking a monoclonal antibody or antibody fragment with a toxic drug with biological activity through a stable linker unit.
  • drug loading can be expressed as the ratio of the amount of drug to the amount of antibody, that is, the average amount of drug conjugated to each antibody in the ADC.
  • the range of drug loading can be 1-20, preferably 1-10 cytotoxic drugs (D) linked to each antibody (Ab).
  • the drug loading is expressed as k, which may be 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or the mean of any two values in between.
  • the average amount of drug per ADC molecule after conjugation can be identified using routine methods such as UV/Vis spectroscopy, mass spectrometry, ELISA assay, monoclonal antibody size variant assay (CE-SDS) and HPLC characterization.
  • the molecular size variant determination method (CE-SDS) of the disclosed monoclonal antibody can adopt the sodium dodecyl sulfate capillary electrophoresis (CE-SDS) ultraviolet detection method, under reducing and non-reducing conditions, according to the molecular weight, according to the capillary electrophoresis method (2015 edition of "Chinese Pharmacopoeia” 0542), quantitatively determine the purity of recombinant monoclonal antibody products.
  • CE-SDS sodium dodecyl sulfate capillary electrophoresis
  • the loading of antibody-drug conjugates can be controlled by the following non-limiting methods, including:
  • antibody refers to an immunoglobulin, which is a tetrapeptide chain structure composed of two identical heavy chains and two identical light chains linked by interchain disulfide bonds.
  • the amino acid composition and sequence of the constant region of the immunoglobulin heavy chain are different, so their antigenicity is also different.
  • immunoglobulins can be divided into five classes, or isotypes, of immunoglobulins, namely IgM, IgD, IgG, IgA, and IgE, and their corresponding heavy chains are mu, delta, and gamma chains, respectively , ⁇ chain, and ⁇ chain.
  • IgG can be divided into different subclasses according to the amino acid composition of its hinge region and the number and position of heavy chain disulfide bonds.
  • IgG can be divided into IgG1, IgG2, IgG3, and IgG4.
  • Light chains are classified as either kappa chains or lambda chains by difference in the constant region.
  • Each of the five Ig classes can have either a kappa chain or a lambda chain.
  • the sequence of about 110 amino acids near the N-terminal of the antibody heavy chain and light chain varies greatly, which is the variable region (Fv region); the rest of the amino acid sequence near the C-terminal is relatively stable, which is the constant region.
  • Fv region variable region
  • the variable region includes 3 hypervariable regions (HVR) and 4 framework regions (FR) with relatively conserved sequences. Three hypervariable regions determine the specificity of antibodies, also known as complementarity determining regions (CDR).
  • Each light chain variable region (LCVR) and heavy chain variable region (HCVR) consists of 3 CDR regions and 4 FR regions, and the sequence from the amino terminal to the carboxyl terminal is: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4.
  • the 3 CDR regions of the light chain refer to LCDR1, LCDR2, and LCDR3; the 3 CDR regions of the heavy chain refer to HCDR1, HCDR2, and HCDR3.
  • Antibodies of the present disclosure include murine antibodies, chimeric antibodies, humanized antibodies and fully human antibodies, preferably humanized antibodies and fully human antibodies.
  • murine antibody in this disclosure refers to an antibody prepared using a mouse according to the knowledge and skill in the art. In preparation, test subjects are injected with the specified antigen, and hybridomas expressing antibodies having the desired sequence or functional properties are isolated.
  • chimeric antibody is an antibody formed by fusing the variable region of a murine antibody with the constant region of a human antibody, which can reduce the immune response induced by the murine antibody.
  • To establish a chimeric antibody it is necessary to first establish a hybridoma that secretes a mouse-derived specific monoclonal antibody, then clone the variable region gene from the mouse hybridoma cell, and then clone the constant region gene of the human antibody as required, and then clone the mouse variable region gene It is connected with the human constant region gene to form a chimeric gene and inserted into an expression vector, and finally expresses the chimeric antibody molecule in a eukaryotic system or a prokaryotic system.
  • humanized antibody also known as CDR-grafted antibody (CDR-grafted antibody) refers to the antibody variable region framework grafted with mouse CDR sequences to humans, that is, different types of human germline antibodies Antibodies generated in the framework sequences. It can overcome the heterologous reaction induced by chimeric antibodies due to carrying a large amount of mouse protein components.
  • framework sequences can be obtained from public DNA databases or published references that include germline antibody gene sequences.
  • Germline DNA sequences such as human heavy and light chain variable region genes can be found in the "VBase" human germline sequence database (available on the Internet at www.mrccpe.com.ac.uk/vbase ), as well as in Kabat, EA, et al.
  • the humanized antibody of the present disclosure also includes the humanized antibody after affinity maturation of CDR by phage display. Further descriptions of methods involving the use of mouse antibodies in humanization include, for example, Queen et al., Proc., Natl. 321, 522 (1986), Riechmann, et al., Nature, 332, 323-327 (1988), Verhoeyen, et al., Science, 239, 1534 (1988)].
  • the development of monoclonal antibodies has gone through four stages, namely: murine monoclonal antibodies, chimeric monoclonal antibodies, humanized monoclonal antibodies and fully human monoclonal antibodies.
  • the present disclosure is a fully human monoclonal antibody.
  • the relevant technologies for the preparation of fully human antibodies mainly include: human hybridoma technology, EBV transformed B lymphocyte technology, phage display technology (phage display), transgenic mouse antibody preparation technology (transgenic mouse) and single B cell antibody preparation technology, etc.
  • antigen-binding fragment refers to one or more fragments of an antibody that retain the ability to specifically bind an antigen. It has been shown that fragments of full-length antibodies can be utilized to perform the antigen-binding function of the antibody.
  • binding fragments included in "antigen-binding fragments" include (i) Fab fragments, monovalent fragments consisting of VL, VH, CL and CH1 domains; (ii) F(ab') 2 fragments, comprising (iii) Fd fragment consisting of VH and CH1 domains; (iv) Fv fragment consisting of VH and VL domains of a single arm of an antibody; (v ) a single domain or dAb fragment (Ward et al., (1989) Nature 341:544-546) consisting of a VH domain; and (vi) isolated complementarity determining regions (CDRs) or (vii) optionally via A combination of two or more isolated CDRs joined by a synthetic linker.
  • CDRs complementarity
  • the two domains VL and VH of the Fv fragment are encoded by separate genes, they can be linked by a synthetic linker using recombinant methods, thus making it possible to produce a single protein in which the VL and VH regions pair to form a monovalent molecule. chain (referred to as single-chain Fv (scFv); see, eg, Bird et al. (1988) Science 242:423-426; and Huston et al. (1988) Proc. Natl. Acad. Sci USA 85:5879-5883).
  • single chain antibodies are also intended to be encompassed within the term "antigen-binding fragment" of an antibody.
  • Antigen-binding portions can be produced by recombinant DNA techniques or by enzymatic or chemical cleavage of intact immunoglobulins.
  • Antibodies can be of different isotypes, eg, IgG (eg, IgGl, IgG2, IgG3, or IgG4 subtype), IgAl, IgA2, IgD, IgE, or IgM antibodies.
  • Fab is an antibody fragment having a molecular weight of about 50,000 and having antigen-binding activity among fragments obtained by treating an IgG antibody molecule with the protease papain (cleaving the amino acid residue at position 224 of the H chain), in which About half and the entire L chain is held together by disulfide bonds.
  • F(ab')2 is an antibody having a molecular weight of about 100,000 and having antigen-binding activity and comprising two Fab regions connected at the hinge position obtained by digesting the lower portion of the two disulfide bonds in the IgG hinge region with the enzyme pepsin fragment.
  • Fab' is an antibody fragment having a molecular weight of about 50,000 and having antigen-binding activity obtained by cleaving the disulfide bond in the hinge region of the above-mentioned F(ab')2.
  • the Fab' fragment can be produced by inserting DNA encoding a Fab' fragment of an antibody into a prokaryote expression vector or a eukaryote expression vector and introducing the vector into a prokaryote or eukaryote to express the Fab'.
  • single-chain antibody single-chain Fv or “scFv” is meant to comprise an antibody heavy chain variable domain (or region; VH) and an antibody light chain variable domain (or region; VL) connected by a linker molecules.
  • Such scFv molecules may have the general structure: NH2 -VL-linker-VH-COOH or NH2 -VH-linker-VL-COOH.
  • Suitable prior art linkers consist of the repeated GGGGS amino acid sequence or variants thereof, for example using 1-4 repeat variants (Holliger et al. (1993), Proc. Natl. Acad. Sci. USA 90:6444-6448) .
  • linkers useful in the present disclosure are described by Alfthan et al. (1995), Protein Eng. 8:725-731, Choi et al. (2001), Eur.J. Immuno 1.31:94-106, Hu et al. (1996) , Cancer Res. 56:3055-3061, described by Kipriyanov et al. (1999), J. Mol. Biol. 293:41-56 and Roovers et al. (2001 ), Cancer Immunol.
  • CDR refers to one of the six hypervariable regions within the variable domain of an antibody that primarily contribute to antigen binding.
  • One of the most commonly used definitions of the six CDRs is provided by Kabat E.A. et al., (1991) Sequences of proteins of immunological interest. NIH Publication 91-3242).
  • the Kabat definition of CDRs applies only to CDR1, CDR2, and CDR3 (CDR L1, CDR L2, CDR L3 or L1, L2, L3) of the light chain variable domain, and to those of the heavy chain variable domain.
  • CDR2 and CDR3 CDR H2, CDR H3 or H2, H3).
  • CDR1, HCDR2, HCDR3 there are three CDRs (HCDR1, HCDR2, HCDR3) in each heavy chain variable region and three CDRs (LCDR1, LCDR2, LCDR3) in each light chain variable region.
  • Amino acid sequence boundaries for CDRs can be determined using any of a variety of well-known schemes, including the "Kabat” numbering convention (see Kabat et al.
  • the CDR amino acid residues in the heavy chain variable domain are numbered 31-35 (HCDR1), 50-65 (HCDR2) and 95-102 (HCDR3);
  • the CDR amino acid residues in the chain variable domain (VL) are numbered 24-34 (LCDR1), 50-56 (LCDR2) and 89-97 (LCDR3).
  • the CDR amino acid numbers in VH are 26-32 (HCDR1), 52-56 (HCDR2) and 95-102 (HCDR3); and the amino acid residues in VL are numbered 26-32 (LCDR1), 50- 52 (LCDR2) and 91-96 (LCDR3).
  • the CDRs consist of amino acid residues 26-35 (HCDR1), 50-65 (HCDR2) and 95-102 (HCDR3) in human VH and amino acid residues 24- 34 (LCDR1), 50-56 (LCDR2) and 89-97 (LCDR3).
  • the numbering of CDR amino acid residues in VH is approximately 26-35 (CDR1), 51-57 (CDR2) and 93-102 (CDR3)
  • the numbering of CDR amino acid residues in VL is approximately 27-32 (CDR1 ), 50-52 (CDR2) and 89-97 (CDR3).
  • the CDR regions of antibodies can be determined using the program IMGT/DomainGap Align.
  • antibody framework refers to the portion of a variable domain VL or VH that serves as a scaffold for the antigen-binding loops (CDRs) of the variable domain. Essentially, it is a variable domain without CDRs.
  • epitope refers to the site on an antigen to which an immunoglobulin or antibody specifically binds.
  • An epitope typically comprises at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 contiguous or non-contiguous amino acids in a unique spatial conformation (see, e.g., Epitope Mapping Protocols in Methods in Molecular Biology, Volume 66, G.E. Morris, Ed. (1996)).
  • antibodies bind with an affinity (KD) of less than about 10" 7M , eg, about less than 10" 8M , 10" 9M or 10" 10M or less.
  • KD affinity
  • nucleic acid molecule refers to DNA molecules and RNA molecules. Nucleic acid molecules can be single-stranded or double-stranded, but are preferably double-stranded DNA. A nucleic acid is "operably linked" when it is placed into a functional relationship with another nucleic acid sequence. For example, a promoter or enhancer is operably linked to a coding sequence if the promoter or enhancer affects the transcription of the coding sequence.
  • vector refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked.
  • the vector is a "plasmid,” which refers to a circular double-stranded DNA loop into which additional DNA segments can be ligated.
  • the vector is a viral vector, wherein additional DNA segments can be ligated into the viral genome.
  • the vectors disclosed herein are capable of autonomous replication in the host cells into which they have been introduced (e.g., bacterial vectors and episomal mammalian vectors with a bacterial origin of replication) or can integrate into the genome of the host cell after introduction, thereby following The host genome is replicated together (eg, non-episomal mammalian vectors).
  • Antigen-binding fragments can also be prepared by conventional methods.
  • one or more human FR regions are added to the non-human CDR region by genetic engineering methods.
  • the human FR germline sequence can be obtained from the website http://imgt.cines.fr of ImMunoGeneTics (IMGT) by comparing the IMGT human antibody variable region germline gene database and MOE software, or from Immunoglobulin Journal, 2001ISBN012441351 get.
  • host cell refers to a cell into which an expression vector has been introduced.
  • Host cells can include bacterial, microbial, plant or animal cells.
  • Bacteria that are readily transformed include members of the enterobacteriaceae such as strains of Escherichia coli or Salmonella; the Bacillaceae such as Bacillus subtilis; Pneumococcus; Streptococcus and Haemophilus influenzae.
  • Suitable microorganisms include Saccharomyces cerevisiae and Pichia pastoris.
  • Suitable animal host cell lines include CHO (Chinese Hamster Ovary cell line) and NSO cells.
  • Antibodies or antigen-binding fragments engineered in the present disclosure can be prepared and purified using conventional methods.
  • cDNA sequences encoding heavy and light chains can be cloned and recombined into GS expression vectors.
  • the recombinant immunoglobulin expression vector can stably transfect CHO cells.
  • mammalian expression systems lead to glycosylation of antibodies, especially at the highly conserved N-terminal site of the Fc region. Positive clones are expanded in serum-free medium in bioreactors for antibody production.
  • the culture fluid from which the antibody has been secreted can be purified by conventional techniques. For example, purify with an A or G Sepharose FF column with adjusted buffer.
  • Antibodies can be concentrated by filtration using conventional methods. Soluble mixtures and aggregates can also be removed by conventional methods such as molecular sieves and ion exchange. The obtained product needs to be immediately frozen, such as -70°C, or freeze-dried.
  • Amino acid sequence identity means that when the amino acid sequences are aligned and gaps are introduced as necessary to achieve the maximum percent sequence identity, and any conservative substitutions are not considered as part of the sequence identity, the difference between a first sequence and a second sequence is The percentage of amino acid residues that are identical to each other. Alignment for purposes of determining percent amino acid sequence identity can be achieved in various ways that are within the skill in the art, for example, using publicly available computer software such as BLAST, BLAST-2, ALIGN, ALIGN-2 or Megalign (DNASTAR) software. Those skilled in the art can determine suitable parameters for measuring alignment, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared.
  • peptide refers to a compound fragment between an amino acid and a protein. It is formed by connecting two or more amino acid molecules through peptide bonds. It is a structural and functional fragment of a protein, such as hormones, enzymes, etc. All peptides.
  • sucrose refers to a biomacromolecule composed of three elements, C, H, and O, and can be divided into monosaccharides, disaccharides, and polysaccharides.
  • fluorescent probe refers to a characteristic fluorescence in the ultraviolet-visible-near-infrared region, and its fluorescence properties (excitation and emission wavelength, intensity, lifetime and polarization, etc.) can vary with the properties of the environment, such as polarity, refractive index A class of fluorescent molecules that can be sensitively changed due to changes in viscosity, viscosity, etc., which can change one or several fluorescent properties by non-covalent interaction with nucleic acid (DNA or RNA), protein or other macromolecular structures, which can be used for research Properties and behavior of macromolecular substances.
  • DNA or RNA nucleic acid
  • protein or other macromolecular structures which can be used for research Properties and behavior of macromolecular substances.
  • alkyl refers to a saturated aliphatic hydrocarbon group which is a straight or branched chain group containing 1 to 20 carbon atoms, preferably an alkyl group containing 1 to 12 carbon atoms, more preferably 1 to 10 carbon atoms atom, most preferably an alkyl group containing 1 to 6 carbon atoms.
  • Non-limiting examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-hexyl, 1-ethyl-2-methylpropyl, and various Branched chain isomers, etc.
  • lower alkyl groups containing 1 to 6 carbon atoms include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl Base, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, etc. .
  • Alkyl groups may be substituted or unsubstituted, and when substituted, substituents may be substituted at any available point of attachment, said substituents being preferably one or more of the following groups independently selected from alkyl radical, alkoxy, halogen, amino, cyano, nitro, hydroxy, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl.
  • heteroalkyl refers to an alkyl group containing one or more heteroatoms selected from N, O or S, wherein alkyl is as defined above.
  • “Monovalent group” means that a compound is “formally” eliminated from a monovalent atom or group.
  • Subunit refers to a compound formed by “formally” eliminating two monovalent or one divalent atoms or atomic groups.
  • Exemplary “alkyl” refers to the part remaining after removing 1 hydrogen atom from an alkane molecule, including linear and branched monovalent groups of 1 to 20 carbon atoms.
  • Alkyl groups containing 1 to 6 carbon atoms non-limiting examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl , 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl and various branched isomers thereof.
  • alkylene refers to a saturated straight or branched chain aliphatic hydrocarbon group having two residues derived from the same carbon atom or two different carbon atoms of a parent alkane by removing two hydrogen atoms, which are A linear or branched chain group containing 1 to 20 carbon atoms, preferably an alkylene group containing 1 to 12 carbon atoms, more preferably an alkylene group containing 1 to 6 carbon atoms.
  • Non-limiting examples of alkylene include, but are not limited to, methylene (-CH 2 -), 1,1-ethylene (-CH(CH 3 )-), 1,2-ethylene (-CH 2 CH 2 )-, 1,1-propylene (-CH(CH 2 CH 3 )-), 1,2-propylene (-CH 2 CH(CH 3 )-), 1,3-propylene (-CH 2 CH 2 CH 2 -), 1,4-butylene (-CH 2 CH 2 CH 2 CH 2 -), and 1,5-butylene (-CH 2 CH 2 CH 2 CH 2 CH 2 -) Wait.
  • Alkylene groups may be substituted or unsubstituted, and when substituted, substituents may be substituted at any available point of attachment, preferably independently and optionally selected from halogen, hydroxy, cyano, amino , one or more of alkyl, chloroalkyl, alkoxy and cycloalkyl.
  • alkenylene is as defined above.
  • alkoxy refers to -O-(alkyl) and -O-(unsubstituted cycloalkyl), wherein alkyl or cycloalkyl is as defined above.
  • alkoxy include: methoxy, ethoxy, propoxy, butoxy, cyclopropoxy, cyclobutoxy, cyclopentyloxy, cyclohexyloxy.
  • Alkoxy may be optionally substituted or unsubstituted, and when substituted, the substituent is preferably one or more of the following groups independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, alkoxy Thio, alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio , Heterocycloalkylthio.
  • cycloalkyl refers to a saturated or partially unsaturated monocyclic or polycyclic cyclic hydrocarbon substituent, the cycloalkyl ring containing 3 to 20 carbon atoms, preferably containing 3 to 12 carbon atoms, more preferably containing 3 to 10 carbon atoms, most preferably contain 3 to 8 carbon atoms.
  • Non-limiting examples of monocyclic cycloalkyls include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, cycloheptyl, cycloheptatriene Base, cyclooctyl, etc.; polycyclic cycloalkyl includes spiro ring, fused ring and bridged ring cycloalkyl.
  • heterocycloalkyl refers to a saturated or partially unsaturated monocyclic or polycyclic cyclic hydrocarbon substituent comprising 3 to 20 ring atoms, one or more of which is selected from nitrogen, oxygen or S(O ) m (where m is an integer from 0 to 2), excluding ring portions of -OO-, -OS- or -SS-, the remaining ring atoms being carbon.
  • the cycloalkyl ring contains 3 to 12 ring atoms, of which 1 to 4 are heteroatoms; more preferably, the cycloalkyl ring contains 3 to 10 ring atoms.
  • Non-limiting examples of monocyclic heterocycloalkyl groups include pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, homopiperazinyl, and the like.
  • Multicyclic heterocycloalkyls include spiro, fused and bridged heterocycloalkyls.
  • spiroheterocycloalkyl refers to a polycyclic heterocycloalkyl group that shares one atom (called a spiro atom) between a 5- to 20-membered monocyclic ring, wherein one or more ring atoms are selected from nitrogen, oxygen or S (O) heteroatoms of m (where m is an integer from 0 to 2), the remaining ring atoms being carbon. It may contain one or more double bonds, but none of the rings has a fully conjugated pi-electron system. Preferably it is 6 to 14 yuan, more preferably 7 to 10 yuan.
  • Spiroheterocycloalkyl is divided into single spiroheterocycloalkyl, double spiroheterocycloalkyl or polyspiroheterocycloalkyl according to the number of spiro atoms shared between rings, preferably single spiroheterocycloalkyl and double spiroheterocycloalkyl Spiroheterocycloalkyl. More preferably, it is a 4-membered/4-membered, 4-membered/5-membered, 4-membered/6-membered, 5-membered/5-membered or 5-membered/6-membered monospiroheterocycloalkyl group.
  • Non-limiting examples of spiroheterocycloalkyl include:
  • fused heterocycloalkyl refers to a 5 to 20 membered polycyclic heterocycloalkyl group in which each ring in the system shares an adjacent pair of atoms with other rings in the system, one or more rings may contain one or Multiple double bonds, but none of the rings have a fully conjugated ⁇ -electron system, wherein one or more ring atoms are heteroatoms selected from nitrogen, oxygen or S(O) m (where m is an integer from 0 to 2), The remaining ring atoms are carbon. Preferably it is 6 to 14 yuan, more preferably 7 to 10 yuan.
  • bicyclic, tricyclic, tetracyclic or polycyclic condensed heterocycloalkyl preferably bicyclic or tricyclic, more preferably 5-membered/5-membered or 5-membered/6-membered bicyclic condensed heterocycloalkane base.
  • fused heterocycloalkyl include:
  • bridged heterocycloalkyl refers to a 5 to 14 membered, polycyclic heterocycloalkyl group of 5 to 14 membered, any two rings sharing two atoms not directly attached, which may contain one or more double bonds, but none of the rings has A fully conjugated ⁇ -electron system wherein one or more ring atoms are heteroatoms selected from nitrogen, oxygen or S(O) m (where m is an integer from 0 to 2) and the remaining ring atoms are carbon.
  • it is 6 to 14 yuan, more preferably 7 to 10 yuan.
  • bridged heterocycloalkyl groups preferably bicyclic, tricyclic or tetracyclic, more preferably bicyclic or tricyclic.
  • bridged heterocycloalkyl groups include:
  • heterocycloalkyl ring may be fused to an aryl, heteroaryl, or cycloalkyl ring where the ring bonded to the parent structure is a heterocycloalkyl, non-limiting examples of which include:
  • Heterocycloalkyl groups may be optionally substituted or unsubstituted, and when substituted, the substituents are preferably one or more of the following groups independently selected from alkyl, alkenyl, alkynyl, alkoxy, Alkylthio, alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio group, heterocycloalkylthio group, oxo group.
  • aryl refers to a 6 to 14 membered all-carbon monocyclic or fused polycyclic (that is, rings sharing adjacent pairs of carbon atoms) group, preferably 6 to 10 membered, having a conjugated pi-electron system, such as benzene and naphthyl, preferably phenyl.
  • the aryl ring may be fused to a heteroaryl, heterocycloalkyl or cycloalkyl ring, where the ring bonded to the parent structure is an aryl ring, non-limiting examples of which include:
  • Aryl groups may be substituted or unsubstituted, and when substituted, the substituents are preferably one or more of the following groups independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, Alkylamino, halogen, mercapto, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocycle Alkylthio.
  • heteroaryl refers to a heteroaromatic system comprising 1 to 4 heteroatoms, 5 to 14 ring atoms, wherein the heteroatoms are selected from oxygen, sulfur and nitrogen.
  • Heteroaryl is preferably 5 to 10 membered, more preferably 5 or 6 membered, such as furyl, thienyl, pyridyl, pyrrolyl, N-alkylpyrrolyl, pyrimidinyl, pyrazinyl, imidazolyl, tetra Azolyl, etc.
  • the heteroaryl ring may be fused to an aryl, heterocycloalkyl or cycloalkyl ring, wherein the ring bonded to the parent structure is a heteroaryl ring, non-limiting examples of which include:
  • Heteroaryl groups may be optionally substituted or unsubstituted, and when substituted, the substituents are preferably one or more of the following groups independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkane Thio, alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio , Heterocycloalkylthio.
  • aminoheterocycloalkyl refers to a heterocycloalkyl group substituted with one or more amino groups, preferably one amino group, wherein heterocycloalkyl group is as defined above, and wherein “amino” refers to -NH2 .
  • aminoheterocycloalkyl refers to a heterocycloalkyl group substituted with one or more amino groups, preferably one amino group, wherein heterocycloalkyl group is as defined above, and wherein “amino” refers to -NH2 .
  • heterocycloalkylamino refers to an amino group substituted by one or more heterocycloalkyl groups, preferably by one heterocycloalkyl group, wherein amino is as defined above, and wherein heterocycloalkyl is as defined above.
  • Representative examples of the present disclosure are as follows:
  • cycloalkylamino refers to an amino group substituted by one or more cycloalkyl groups, preferably by one cycloalkyl group, wherein amino group is as defined above and wherein cycloalkyl group is as defined above.
  • Representative examples of the present disclosure are as follows:
  • cycloalkylalkyl refers to an alkyl group substituted by one or more cycloalkyl groups, preferably by one cycloalkyl group, wherein alkyl is as defined above, and wherein cycloalkyl is as defined above.
  • haloalkyl refers to an alkyl group substituted with one or more halogens, wherein alkyl is as defined above.
  • deuteroalkyl refers to an alkyl group substituted with one or more deuterium atoms, wherein alkyl is as defined above.
  • hydroxyl refers to a -OH group.
  • halogen refers to fluorine, chlorine, bromine or iodine.
  • amino refers to -NH2 .
  • nitro refers to -NO2 .
  • Optional or “optionally” means that the subsequently described event or circumstance can but need not occur, and that the description includes instances where the event or circumstance occurs or does not occur.
  • a heterocycloalkane group optionally substituted with an alkyl group means that an alkyl group may but need not be present, and the specification includes cases where the heterocycloalkane group is substituted with an alkyl group and where the heterocycloalkane group is not substituted with an alkyl group. situation of replacement.
  • Substituted means that one or more hydrogen atoms, preferably up to 5, more preferably 1 to 3 hydrogen atoms in a group are independently substituted by a corresponding number of substituents. It goes without saying that substituents are only in their possible chemical positions and that a person skilled in the art can determine (by experiment or theory) possible or impossible substitutions without undue effort. For example, an amino or hydroxyl group with free hydrogen may be unstable when bonded to a carbon atom with an unsaturated (eg, ethylenic) bond.
  • pharmaceutically acceptable salt refers to a salt of the antibody-drug conjugate of the present disclosure, or a salt of a compound described in the present disclosure, which has the following properties when used in a mammal. Safety and efficacy, and have proper biological activity.
  • the antibody-drug conjugate of the present disclosure contains at least one amino group, so it can form salts with acids.
  • pharmaceutically acceptable salts include: hydrochloride.
  • solvate means that the ligand-drug conjugate compound of the present disclosure forms a pharmaceutically acceptable solvate with one or more solvent molecules.
  • solvent molecules include water, ethanol, acetonitrile, isopropyl alcohol, DMSO, ethyl acetate.
  • drug carrier used in the drug of the present disclosure refers to a system that can change the way the drug enters the human body and distributes the drug in the body, controls the release rate of the drug, and delivers the drug to the target organ.
  • Drug carrier release and targeting system can reduce drug degradation and loss, reduce side effects, and improve bioavailability.
  • polymer surfactants that can be used as carriers can self-assemble and form various forms of aggregates due to their unique amphiphilic structure. Preferred examples are micelles, microemulsions, gels, liquid crystals, vesicles, etc. . These aggregates have the ability to entrap drug molecules, and at the same time have good permeability to the membrane, which can be used as excellent drug carriers.
  • excipient is an add-on in a pharmaceutical preparation other than the main drug, and can also be called an adjuvant.
  • adjuvant such as binders, fillers, disintegrants, lubricants in tablets; matrix parts in semi-solid ointments and creams; preservatives, antioxidants, flavoring agents, fragrances, Solubilizers, emulsifiers, solubilizers, osmotic pressure regulators, colorants, etc. can all be called excipients.
  • the term "diluent” is also known as filler and its main purpose is to increase the weight and volume of the tablet. The addition of the diluent not only ensures a certain volume, but also reduces the dose deviation of the main components and improves the compression molding properties of the drug. When the drug in the tablet contains oily components, an absorbent needs to be added to absorb the oily substance, so as to keep it in a "dry” state, so as to facilitate making tablets.
  • Residues in HER2 antibody binding domain II (and optionally also binding to other domains than the extracellular domain of HER2, such as residues in domains I and III) that "bind to the heterodimer binding site of HER2" , and at least to some extent can sterically hinder the formation of HER2-EGFR, HER2-HER3 or HER2-HER4 heterodimers.
  • an antibody that "binds to domain II of HER2" binds residues in domain II and optionally other domains of HER2, such as residues in domains I and III.
  • antibodies that bind domain II bind to the junction between domains I, II and III of HER2.
  • Pertuzumab refers to an antibody comprising the light and heavy chain variable region amino acid sequences in SEQ ID No. 1 and 2, respectively. If Pertuzumab is a whole antibody, it preferably comprises the light and heavy chain amino acid sequences in SEQ ID Nos. 3 and 4, respectively. “Pertuzumab” refers to an antibody comprising the light and heavy chain variable region amino acid sequences in SEQ ID Nos. 1 and 2, respectively. “Trastuzumab” of the present disclosure is comprised of light chain and heavy chain amino acid sequences in SEQ ID Nos. 5 and 6, respectively. For the preparation method, refer to WO2006033700 and the relevant content is incorporated herein for illustration.
  • Fig. 1 is a diagram showing the change of tumor volume in N87/16-8 subcutaneously transplanted tumor model mice.
  • Fig. 2 is a graph showing the body weight change of N87/16-8 subcutaneously transplanted tumor model mice.
  • Fig. 3 is a graph showing the change in tumor volume of JIMIT-1 subcutaneously transplanted tumor model mice.
  • Fig. 4 is a graph showing the body weight change of JIMIT-1 subcutaneously transplanted tumor model mice.
  • NMR nuclear magnetic resonance
  • MS mass spectroscopy
  • MS was determined with Agilent 1200/1290 DAD-6110/6120 Quadrupole MS liquid mass spectrometer (manufacturer: Agilent, MS model: 6110/6120 Quadrupole MS).
  • HPLC High performance liquid chromatography
  • Chiral HPLC analysis was performed using an Agilent 1260 DAD high performance liquid chromatograph.
  • the CombiFlash rapid preparation instrument uses Combiflash Rf200 (TELEDYNE ISCO).
  • the thin-layer chromatography silica gel plate uses Yantai Huanghai HSGF254 or Qingdao GF254 silica gel plate.
  • the specification of the silica gel plate used in thin-layer chromatography (TLC) is 0.15mm to 0.2mm, and the specification of thin-layer chromatography separation and purification products is 0.4mm. to 0.5mm.
  • Silica gel column chromatography generally uses Yantai Huanghai silica gel 200 to 300 mesh silica gel as the carrier.
  • the known starting materials of the present invention can be adopted or synthesized according to methods known in the art, or can be purchased from ABCR GmbH & Co.KG, Acros Organics, Aldrich Chemical Company, Shaoyuan Chemical Technology (Accela ChemBio Inc), Darui chemical companies.
  • the reactions can all be carried out under an argon atmosphere or a nitrogen atmosphere.
  • the argon atmosphere or nitrogen atmosphere means that the reaction bottle is connected to an argon or nitrogen balloon with a volume of about 1 L.
  • the hydrogen atmosphere means that the reaction bottle is connected to a hydrogen balloon with a capacity of about 1L.
  • the pressurized hydrogenation reaction uses Parr 3916EKX hydrogenation instrument and Qinglan QL-500 hydrogen generator or HC2-SS hydrogenation instrument.
  • the hydrogenation reaction is usually vacuumized and filled with hydrogen, and the operation is repeated 3 times.
  • the solution refers to an aqueous solution.
  • reaction temperature is room temperature, ranging from 20°C to 30°C.
  • the eluent system of column chromatography and the developing agent system of thin layer chromatography used for purifying compounds include: A: dichloromethane and isopropanol system, B: dichloromethane and methanol system, C: petroleum ether and In the ethyl acetate system, the volume ratio of the solvent is adjusted according to the polarity of the compound, and it can also be adjusted by adding a small amount of triethylamine and acidic or alkaline reagents.
  • compound 1a (eribulin, prepared by referring to ZL201010236637.2) (72.91 mg, 0.1 mmol) was dissolved in 10 mL of tetrahydrofuran, and Fmoc-OSu (fluorenylmethoxycarbonyl succinimide, 41mg, 0.12mmol), and then stirred at room temperature until the reaction was complete. Concentrate under reduced pressure to obtain a crude product, which is directly used in the next reaction.
  • Fmoc-OSu fluorenylmethoxycarbonyl succinimide
  • reaction solution was purified by high performance liquid chromatography (separation conditions: chromatographic column: XBridge Prep C18 OBD 5um 19*250mm; mobile phase: A-water (10mmol NH 4 OAc): B-acetonitrile, gradient elution, flow rate: 18mL/ min), the corresponding components were collected and concentrated under reduced pressure to obtain the title product L-2A: 2.4 mg, L-2B: 1.7 mg).
  • Embodiment 5 ADC-004
  • Embodiment 6 ADC-005
  • Test Example 1 Inhibitory effect on the proliferation of human breast cancer BT-474 and human gastric cancer NCI-N87, NCI-N87/16-8, NCI-N87/8-2 cells cultured in vitro
  • sequence drug code concentration% purity% 1 ADC-001 1.16 96.06 2 ADC002 1.06 95.13 3 ADC-003 1.21 98.18 4 ADC-004 1.24 97.57 5 ADC-005 5 / 6 kadcyla 10 /
  • NCI-N87 and BT-474 cells were purchased from American Type Culture Collection (ATCC).
  • ATCC American Type Culture Collection
  • the T-DM1 resistant NCI-N87/16-8 and NCI-N87/8-2 cells induced by T-DM1 long-term effect on NCI-N87 were constructed by our laboratory. Cells were cultured in RPMI 1640/DMEM (1:1) medium containing 10% fetal bovine serum (FBS).
  • FBS fetal bovine serum
  • RPMI 1640 and DMEM were purchased from Gibco BRL; FBS was purchased from Gibco; sulforhodamine B (SRB) was purchased from Sigma.
  • Microplate reader Synergy H4 was purchased from BioTek.
  • Inhibition rate (OD value control well - OD value administration well) / OD value control well ⁇ 100%
  • the half inhibitory concentration IC 50 was calculated with GraphPad Prism 7 software.
  • CTG was used to detect the ATP content, reflecting the survival of tumor cells.
  • the final culture conditions were determined based on IC50 and maximum inhibition rate by seeding cells at different densities and culturing for 3 days and 5 days. Then, according to this condition, the killing effect of the toxin molecule is detected.
  • SKBR3 tumor cells HER2+, ATCC, product number HTB-30
  • MDA-MB-468 HER2-, ATCC, product number HTB-132
  • A549 human Non-small cell lung cancer cells, ATCC, Cat. No. CCL-185
  • Cell culture A549, SK-BR-3 and MDA-MB-468 cells were respectively cultured with Ham's F-12K (Kaighn's) medium (Gibco, 21127030) and McCoy's 5A containing 10% FBS (Gibco, 10099-141) culture medium (ThermoFisher, product number 16600108) and Leibovitz's L-15 medium (ThermoFisher, product number 11415-114).
  • Ham's F-12K Ham's F-12K (Kaighn's) medium (Gibco, 21127030) and McCoy's 5A containing 10% FBS (Gibco, 10099-141) culture medium (ThermoFisher, product number 16600108) and Leibovitz's L-15 medium (ThermoFisher, product number 11415-114).
  • Cell plating A549 was digested with trypsin, terminated with the above-mentioned medium, and after counting, 4.3 ⁇ 10 5 , 7.2 ⁇ 10 5 , and 11.5 ⁇ 10 5 cells were respectively added to culture medium to make the final volume 26 ml. Add 180ul of cell suspension to each well of the 2nd column to the 11th column of a 96-well plate (Corning, Cat. No. 3903), so that the cell density is 3K, 5K, and 8K per well, respectively. Column 12 is 200ul culture solution, and the remaining wells are filled with PBS. Repeat the above operations for SKBR3 and MDA-MB-468 cells. Make two parallel copies.
  • CTG detection Cell Titer-GloTM, luminescent cell viability detection, Promega Company: take out the cell plate on the 3rd and 5th day respectively, and equilibrate to room temperature. Add 90ul of CTG to each well, and react for 10min at room temperature in the dark, read the luminescence value with a microplate reader and calculate the IC 50 .
  • a group of dogs were intravenously administered Compound D-1, the dosage was 0.5 mg/kg, and the volume was 2 ml/kg.
  • Another group of dogs was administered eribulin intravenously, the dosage was 0.5mg/kg, and the volume of administration was 2ml/kg.
  • Compound D-1 was administered to dogs by injection, and 1ml of blood was collected before administration and at 5 minutes, 0.25, 0.5, 1.0, 2.0, 4.0, 8.0, 12.0, and 24.0 hours after administration, and the collected blood samples were placed in EDTA-K2 anti- Put the collected whole blood on ice in coagulation blood collection tubes, and centrifuge the plasma within 1 hour (centrifugal force 2200g, centrifugation 10min, 2-8°C). Plasma samples were stored in a -80°C freezer before testing.
  • Determination of the test compound content in dog plasma after drug injection administration get 25 ⁇ l of dog plasma at each moment after administration, add internal standard solution camptothecin (China Institute for the Control of Biological Products) 50 ⁇ l (100ng/mL) and acetonitrile 200 ⁇ l, Vortex and mix for 5 minutes, centrifuge for 10 minutes (3700 rpm), and take 3-4 ⁇ l of the supernatant from the plasma sample for LC/MS/MS (API4000 triple quadrupole tandem mass spectrometer (No.2), Applied Biosystems, USA ; Shimadzu LC-30AD ultra-high performance liquid chromatography system, Japan Shimadzu company) analysis.
  • LC/MS/MS API4000 triple quadrupole tandem mass spectrometer
  • Test Example 4 Efficacy of ADC-004 on human gastric cancer NCI-N87/16-8 subcutaneously transplanted tumors in nude mice
  • ADC-004 diluted to the required concentration with normal saline.
  • NCI-N87 cells were purchased from American Type Culture Collection. NCI-N87 was resistant to T-DM1 after long-term T-DM1 induction and culture, and was named NCI-N87/16-8. The cells were cultured in a 10-cm dish, and the culture conditions were RPMI 1640 medium (Gibco) plus 10% fetal bovine serum, penicillin and streptomycin, and cultured at 37°C in an incubator containing 5% CO 2 air. Subculture 2-3 times a week, when the cells are in the exponential growth phase, trypsinize, collect the cells, count and inoculate.
  • RPMI 1640 medium Gibco
  • 10% fetal bovine serum penicillin and streptomycin
  • BALB/cJGpt-Foxn1 nu /Gpt mice 4 weeks old, female, were purchased from Jiangsu Jicui Yaokang Biotechnology Co., Ltd. Production license number: SCXK (Su) 2019-0009; animal certificate number 202004958. Breeding environment: SPF grade.
  • Each nude mouse was subcutaneously inoculated with 1 ⁇ 10 7 NCI-N87/16-8 cells, and after the tumor grew to 100-150 mm 3 , the animals were divided into groups according to tumor volume and body weight (D0). Mice were given 0.3 and 0.6 mg/ml of ADC-004 by intravenous injection, and the administration volume was 10 mL/kg. The tumor volume was measured twice a week, the body weight of the mice was weighed, and the data were recorded.
  • the experimental index is to investigate the effect of the drug on tumor growth, and the specific index is T/C% or tumor growth inhibition rate TGI (%).
  • the tumor diameter was measured with a vernier caliper twice a week, and the formula for calculating the tumor volume (V) was:
  • V 1/2 ⁇ a ⁇ b 2 where a and b represent length and width respectively.
  • T/C (%) (TT 0 )/(CC 0 ) ⁇ 100
  • T, C are the tumor volumes at the end of the experiment
  • T 0 , C 0 are the tumor volumes at the beginning of the experiment.
  • growth inhibition rate TGI(%) 100-(TT 0 )/T 0 ⁇ 100
  • T ⁇ T 0 or C ⁇ C 0 it is defined as partial tumor regression (PR); if the tumor completely disappears, it is defined as complete tumor regression (CR).
  • the two-tailed Student’s t test was used to compare the tumor volumes of the two groups, and P ⁇ 0.05 was defined as a statistically significant difference.
  • ADC-004 can inhibit the growth of NCI-N87/16-8 cells in the nude mouse subcutaneous xenograft tumor model, and the tumor inhibition rates were 46.77% and 90.18% (P ⁇ 0.01 vs PBS control). Tumor-bearing mice tolerated ADC-004 well, and no symptoms such as weight loss occurred.
  • ADC-004 can effectively inhibit the growth of human gastric cancer NCI-N87/16-8 cells in the subcutaneous xenograft model of nude mice, and the tumor-bearing mice can tolerate ADC-004 well.
  • Test Example 5 Efficacy of ADC-004 on JIMIT-1 Cell Subcutaneously Transplanted Tumors in Nude Mice
  • ADC-004 diluted to the desired concentration with PBS.
  • mice were subcutaneously inoculated with 5 ⁇ 10 5 JIMT1 cells on the right back, and when the tumor volume reached 80-100 mm 3 , they were randomly divided into groups according to tumor volume and mouse weight, with 6 mice in each group, and the administration began on the day of grouping .
  • HRA00092-C063-004 was diluted with PBS to 0.6mg/ml for intravenous injection, and the administration volume was 10ml/kg, and the control group was given the same volume of PBS by intravenous injection.
  • the long and short diameters of the tumors were measured with a vernier caliper twice a week, and the body weight of the mice was measured.
  • V 1/2 ⁇ a ⁇ b 2 where a and b represent length and width respectively.
  • T/C (%) (TT 0 )/(CC 0 ) ⁇ 100
  • T, C are the tumor volumes at the end of the experiment
  • T 0 , C 0 are the tumor volumes at the beginning of the experiment.
  • ADC-004 could significantly inhibit the growth of JIMIT-1 cells in the subcutaneous xenograft tumor model of nude mice, with a tumor inhibition rate of 121.3%, and the tumors in 5 mice all regressed ( ⁇ 50mm 3 ). Tumor-bearing mice tolerated ADC-004 well, and no symptoms such as weight loss occurred.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

一种艾日布林衍生物的药物偶联物。具体而言，提供了艾日布林衍生物与HER2的结构域II结合的HER2抗体偶联物、其制备方法及其在医药上的应用。进一步涉及通过施用所述的抗体-药物偶联物，用于治疗癌症的方法和组合物。

Description

艾日布林衍生物的药物偶联物 技术领域
本公开涉及艾日布林衍生物的药物偶联物。
背景技术
抗体药物偶联物(antibody drug conjugate，ADC)把单克隆抗体或者抗体片段通过稳定的化学接头化合物与具有生物活性的药物相连，充分利用了抗体对正常细胞和肿瘤细胞表面抗原结合的特异性和药物的高效性，同时又避免了前者疗效偏低和后者毒副作用过大等缺陷。这也就意味着，与以往传统的化疗药物相比，抗体药物偶联物能精准地结合肿瘤细胞并降低将对正常细胞的影响。
至2000年第一个抗体药物偶联物Mylotarg(吉妥珠单抗奥唑米星(gemtuzumab ozogamicin)，惠氏制药有限公司)被美国FDA批准上市用于治疗急性髓细胞白血病开始，进入临床阶段的ADC药物共有164项，大多数(n＝100)处于临床一期，46项进入临床二期，7项进入临床三期，BLA申请药物有3项。三代上市的代表药物分别是基因泰克和Genetics公司合作开发的Polatuzumab vedotin(商品名，Polivy，2019年6月获批上市)，Agensys(安斯泰来的子公司)和Seattle Genetics合作开发的Enfortumab vedotin(商品名，Padcev，2019年12月)以及第一三共开发的Fam-trastuzumab deruxtecan(商品名，Enhertu)。
微管为与包括细胞内迁移和转运、细胞信号传导和维持细胞形状的多种细胞功能相关的有力的细丝状细胞骨架蛋白。微管也在有丝分裂细胞分裂中通过形成染色体分成两个子细胞所需的有丝分裂纺锤体而起到关键作用。所有细胞中微管的生物功能大部分由其聚合动力学调节，这通过α和β微管蛋白二聚物可逆、非共价地加在微管两端进行。这种动力学行为和所产生的对微管长度的控制为有丝分裂纺锤体的适当功能所不可缺少的。甚至微管动力学的微小改变也会牵涉轴检查点，抑制有丝分裂时细胞周期进展，且随后引起细胞死亡。由于癌细胞的细胞分裂快速，所以与正常细胞相比，其一般对结合于微管蛋白且破坏其正常功能的化合物更加敏感。因此，微管蛋白抑制剂和其它靶向微管剂有望成为一类治疗癌症的药物。
发明内容
本公开提供了一种抗体-药物偶联物(ADC)，其具有式(I)所示结构或其药学上可接受的盐或溶剂化物：
Ab-(L-D) k
(I)
其中，Ab为与HER2的结构域II结合的HER2抗体或其抗原结合片段，
L为将Ab共价连接于D的连接子，且k为1至20(包括1、2、3、4、5、6、7、8、9、10、11、12、13、14、15、16、17、18、19、20或任意两数值之间任意数值)，
-D如式所示：
Figure PCTCN2022107479-appb-000001
在一些实施方案中，抗体-药物偶联物Ab-(L-D) k中k选自1至10，可以为整数，也可以为小数。
在一些实施方案中，连接子在细胞外是稳定的，使得ADC在存在于细胞外环境中时保持完整，但在例如癌细胞的细胞中内化时能够裂解。在一些实施方案中，当ADC进入表达对ADC的抗体部分具有特异性的抗原的细胞时，艾日布林衍生物药物部分从抗体部分裂解，且裂解释放艾日布林衍生物的未修饰形式。
在一些实施方案中，连接子中的可裂解部分为可裂解肽部分。在一些实施方案中，相对于包含其他可裂解部分的ADC，包含可裂解肽部分的ADC显示较低的聚集水平，改善的抗体：药物比率，增加的癌细胞的靶向杀死，减少的非癌细胞的脱靶杀死，和/或较高的药物负载。在一些实施方案中，相对于不可裂解的连接子，添加可裂解部分增加细胞毒性和/或效力。在一些实施方案中，可裂解肽部分能够由酶裂解，且连接子为酶能够裂解的连接子。在一些实施方案中，酶为组织蛋白酶，且连接子为组织蛋白酶能够裂解的连接子。在某些实施方案中，与其他分裂机制相比，酶能够裂解的连接子(例如组织蛋白酶能够裂解的连接子)显示上述改善特性中的一种或多种。
在一些实施方案中，连接子包含氨基酸单元，所述氨基酸单元优选包含由2至7个选自苯丙氨酸、甘氨酸、缬氨酸、赖氨酸、瓜氨酸、丝氨酸、谷氨酸、天冬氨酸的氨基酸构成的肽残基，更优选缬氨酸-瓜氨酸(Val-Cit)、丙氨酸-丙氨酸-天冬酰胺(Ala-Ala-Asn)、甘氨酸-甘氨酸-赖氨酸(Gly-Gly-lys)、缬氨酸-赖氨酸(Val-lys)、缬氨酸-丙氨酸(Val-Ala)、缬氨酸-苯丙氨酸(Val-Phe)或甘氨酸-甘氨酸-苯丙氨酸-甘氨酸(Gly-Gly-Phe-Gly)。
在一些实施方案中，本公开包括氨基酸单元的连接子选自：
Figure PCTCN2022107479-appb-000002
在一些实施方案中，氨基酸单元包含缬氨酸-瓜氨酸(Val-Cit)。在一些实施方案中，相对于包含其它氨基酸单元或其它可裂解部分的ADC，包含Val-Cit的ADC 显示增加的稳定性，减少的脱靶细胞杀死，增加的靶向细胞杀死，较低的聚集水平，和/或较高的药物负载。
另一方面，一些实施方案提供的连接子包含可裂解磺酰胺部分，所述连接子在还原条件下能够裂解。
在一些实施方案中，所述连接子包含可裂解二硫化物部分，所述连接子在还原条件下能够裂解。
另一方面，本公开抗体偶联物中连接子包含至少一种将艾日布林衍生物D连接于可裂解部分的间隔单元。在一些实施方案中，所述连接子包含连接于D的间隔单元。
在一些实施方案中，所述间隔单元包含对氨基苯甲氧基羰基(pAB)，
Figure PCTCN2022107479-appb-000003
在一些实施方案中，所述间隔单元包含：
Figure PCTCN2022107479-appb-000004
其中，Z 1至Z 4各自独立地选自碳原子或氮原子；R 4选自烷基、环烷基、芳基和杂芳基，所述的烷基、环烷基、芳基和杂芳基各自独立地任选被选自烷基、烷氧基、卤素、氨基、氰基、硝基、羟基、羟烷基、环烷基、杂环烷基、芳基和杂芳基中的一个或多个取代基所取代；R 1和R 2各自独立选自氢、C 1-6烷基、卤代烷基或C 3-6环烷基，优选氢；或者，R 1与R 2与其相连接的碳原子一起形成C 3-6环烷基；X选自-O-或-NH-；L选自1-4之间整数；
Q为V-E，V-E提供了可被位于胞内的糖苷酶切割的糖苷键，E选自-O-、-S-或-NR 3-，R 3选自氢或甲基，进一步地，V选自
Figure PCTCN2022107479-appb-000005
其中R 5选自-COOH或CH 2OH。在一些实施方案中，V选自-COOH。
在一些实施方案中，所述间隔单元包含：
Figure PCTCN2022107479-appb-000006
Figure PCTCN2022107479-appb-000007
另一方面，本公开抗体偶联物(ADC)中L-D是由下式表示的化学部分：
-Str-(Pep)-Sp-D
Str是与Ab共价连接的伸展基单元，
Sp为间隔单元，
Pep选自氨基酸单元。
另一方面，ADC中Str选自下式表示的化学部分：
Figure PCTCN2022107479-appb-000008
其中R 6选自-W-C(O)-、-C(O)-W-C(O)-、(CH 2CH 2O) p1C(O)-、(CH 2CH 2O) p1CH 2C(O)-、(CH 2CH 2O) p1CH 2CH 2C(O)-，其中W选自C 1-8亚烷基、C 1-8亚烷基-环烷基或1至8个原子的直链杂亚烷基，所述杂亚烷基包含1至3个选自N、O或S的杂原子，其中所述的C 1-8亚烷基、C 1-8亚烷基-环烷基和直链杂亚烷基各自独立地任选进一步被选自卤素、羟基、氰基、氨基、烷基、氯代烷基、烷氧基和环烷基的一个或多个取代基所取代；
L 1选自-NR 7(CH 2CH 2O) p1CH 2CH 2C(O)-、-NR 7(CH 2CH 2O) p1CH 2C(O)-、-S(CH 2) p1C(O)-、-(CH 2) p1C(O)-或化学键，优选化学键；其中，p1为1至20的整数，R 7选自氢原子、烷基、卤代烷基和羟烷基。
在一些实施方案中，连接子可以包含至少一种聚乙二醇(PEG)部分。PEG部分可以例如包含-(PEG) p1-，
Figure PCTCN2022107479-appb-000009
其中p1为整数1至20，例如
Figure PCTCN2022107479-appb-000010
(PEG) 2；
Figure PCTCN2022107479-appb-000011
(PEG) 4；
Figure PCTCN2022107479-appb-000012
(PEG) 5。
在一些实施方案中，连接子中的间隔子单元包含(PEG) 2。在一些实施方案中，尽管连接子长度较短，但相对于包含较长间隔子单元(例如(PEG) 8)的ADC，包含较短间隔子单元(例如(PEG) 2)的ADC显示较低的聚集水平和/或较高的药物负载。
在一些实施方案中，所述抗体-药物偶联物中R 7选自C 1-6亚烷基C(O)-、-(CH 2-CH 2O) 2C(O)-、-(CH 2-CH 2O) 2CH 2C(O)-、-(CH 2-CH 2O) 2CH 2CH 2C(O)-、-(CH 2-CH 2O) 3C(O)-和-(CH 2-CH 2O) 4C(O)-。
在一些实施方案中，所述抗体-药物偶联物中连接子L包含：顺丁烯二酰亚胺-(PEG) 2-Val-Cit、顺丁烯二酰亚胺-(PEG) 6-Val-Cit、顺丁烯二酰亚胺-(PEG) 8-Val-Cit、顺丁烯二酰亚胺-(PEG) 4-CH 2CH 2C(O)-Val-lys、顺丁烯二酰亚胺-(CH 2) 5-Val-Cit、顺 丁烯二酰亚胺-(CH 2) 5-Val-lys、顺丁烯二酰亚胺-(CH 2) 5-Gly-Gly-Phe-Gly、顺丁烯二酰亚胺-(PEG) 2-Ala-Ala-Asn、顺丁烯二酰亚胺-(PEG) 6-Ala-Ala-Asn、顺丁烯二酰亚胺-(PEG) 8-Ala-Ala-Asn、顺丁烯二酰亚胺-(PEG) 4-三唑-(PEG) 3-磺酰胺、顺丁烯二酰亚胺-(PEG) 2-CH 2CH 2C(O)-Val-lys、顺丁烯二酰亚胺-(PEG) 4-三唑-(PEG) 3-磺酰胺或Mal-(PEG) 4-三唑-(PEG) 3-二硫化物。
另一方面，一些实施方案提供所述抗体-药物偶联物中Str选自下式表示的化学部分：
Figure PCTCN2022107479-appb-000013
其中R 8选自C 1-10亚烷基、C 2-10烯基、(C 1-10亚烷基)O-、N(R d)-(C 2-6亚烷基)-N(R d)和N(R d)-(C 2-6亚烷基)；且每个R d独立为H或C 1-C 6烷基。
在一些实施方案中，所述抗体-药物偶联物，其由下式表示：
Figure PCTCN2022107479-appb-000014
k选自1至10，可以为整数，也可以为小数；p1选自2、4、6或8；p2选自0、1或2；
Figure PCTCN2022107479-appb-000015
k选自1至10，可以为整数，也可以为小数；p1选自2、4、6或8；p2选自0、1或2；
Figure PCTCN2022107479-appb-000016
k选自1至10，可以为整数，也可以为小数；p1选自2、4、6或8；p2选自0、1或2；
Figure PCTCN2022107479-appb-000017
k选自1至10，可以为整数，也可以为小数；p2选自1-6之间整数；
Figure PCTCN2022107479-appb-000018
k选自1至10，可以为整数，也可以为小数；p2选自1-6之间整数；
Figure PCTCN2022107479-appb-000019
k选自1至10，可以为整数，也可以为小数；p2选自1-6之间整数。
进一步地，本公开所述抗体-药物偶联物(ADC)选自：
Figure PCTCN2022107479-appb-000020
Figure PCTCN2022107479-appb-000021
Figure PCTCN2022107479-appb-000022
其中，k选自1至10，可以为整数，也可以为小数。
前述HER2的结构域II结合的HER2抗体或其抗原结合片段重、轻链的可变区序列如下所示：
轻链可变区
Figure PCTCN2022107479-appb-000023
重链可变区
Figure PCTCN2022107479-appb-000024
以下为Pertuzumab的序列：
轻链
Figure PCTCN2022107479-appb-000025
Figure PCTCN2022107479-appb-000026
重链
Figure PCTCN2022107479-appb-000027
以下为Trastuzumab的序列：
轻链
Figure PCTCN2022107479-appb-000028
重链
Figure PCTCN2022107479-appb-000029
在一些实施方案中，本公开抗体偶联物中k选自2.0至2.5，包括2.0、2.1、2.2、2.3、2.4、2.5或任意两数之间值。
在另一些实施方案中，本公开抗体偶联物中k选自2.5至3.5，包括2.5、2.6、2.7、2.8、2.9、3.0、3.1、3.2、3.3、3.4、3.6、3.7、3.8、3.9、4.0或任意两数之间值。
在另一些实施方案中，本公开抗体偶联物中k选自3.5至5.0，包括3.5、3.6、3.7、3.8、3.9、4.0、4.1、4.2、4.3、4.4、4.5、4.6、4.7、4.8、4.9、5.0或任意两数 之间值。
另一方面，本公开还提供前述抗体-偶联物的同位素取代物。在一些实施方案中，所述同位素取代物为氘原子取代的。
另一方面，本公开还提供一种药物组合物，其含有治疗有效量的前述抗体-药物偶联物，或其同位素取代物，以及药学上可接受的载体、稀释剂或赋形剂。
在一些实施方案中，所述的药物组合物的单位剂量为0.001mg-1000mg。
在某些实施方案中，基于组合物的总重量，所述的药物组合物含有0.01-99.99％的前述抗体-药物偶联物，或其同位素取代物。在某些实施方案中，所述的药物组合物含有0.1-99.9％的前述抗体-药物偶联物，或其同位素取代物。在某些实施方案中，所述的药物组合物含有0.5％-99.5％的前述抗体-药物偶联物，或其同位素取代物。在某些实施方案中，所述的药物组合物含有1％-99％的前述抗体-药物偶联物，或其同位素取代物。在某些实施方案中，所述的药物组合物含有2％-98％的前述抗体-药物偶联物，或其同位素取代物。
在某些实施方案中，基于组合物的总重量，所述的药物组合物含有0.01％-99.99％的药学上可接受的赋形剂。在某些实施方案中，所述的药物组合物含有0.1％-99.9％的药学上可接受的赋形剂。在某些实施方案中，所述的药物组合物含有0.5％-99.5％的药学上可接受的赋形剂。在某些实施方案中，所述的药物组合物含有1％-99％的药学上可接受的赋形剂。在某些实施方案中，所述的药物组合物含有2％-98％的药学上可接受的赋形剂。
本公开还提供一种前述抗体-药物偶联物或前述药物组合物在制备用于治疗或预防肿瘤的药物中的用途。在一些实施方案中，所述的肿瘤为与HER2的结构域II表达相关的癌症。
本公开还提供一种前述抗体-药物偶联物或前述药物组合物在制备治疗和/或预防癌症的药物中的用途。在一些实施方案中，所述癌症选自乳腺癌、卵巢癌、宫颈癌、子宫癌、前列腺癌、肾癌、尿道癌、膀胱癌、肝癌、胃癌、子宫内膜癌、唾液腺癌、食道癌、黑色素瘤、神经胶质瘤、神经母细胞瘤、肉瘤、肺癌、结肠癌、直肠癌、结直肠癌、白血病、骨癌、皮肤癌、甲状腺癌、胰腺癌和淋巴瘤。
本公开还提供一种治疗或预防与HER2的结构域II表达相关的癌症患者的方法，其通过向所述患者施用治疗有效量的如前述抗体-药物偶联物，或其同位素取代物，或前述药物组合物。
本公开还提供了用于治疗或预防与HER2的结构域II表达相关的癌症的前述抗体-药物偶联物，或其同位素取代物，或前述药物组合物。
可将活性化合物制成适合于通过任何适当途径给药的形式，活性化合物优选是以单位剂量的方式，或者是以患者可以以单剂自我给药的方式。本发明化合物或组合物的单位剂量的表达方式可以是片剂、胶囊、扁囊剂、瓶装药水、药粉、颗粒剂、锭剂、栓剂、再生药粉或液体制剂。
发明的详细说明
除非另有限定，本公开所用的所有技术和科学术语均与本公开所属领域普通技术人员的通常理解一致。虽然也可采用与本公开所述相似或等同的任何方法和材料实施或测试本公开，但本公开描述了优选的方法和材料。描述和要求保护本公开时，依据以下定义使用下列术语。
当本公开中使用商品名时，申请人旨在包括该商品名产品的制剂、该商品名产品的非专利药和活性药物部分。
除非有相反陈述，在说明书和权利要求书中使用的术语具有下述含义。
本公开化合物可以存在特定的几何或立体异构体形式。本公开设想所有的这类化合物，包括顺式和反式异构体、(-)-和(+)-对对映体、(R)-和(S)-对映体、非对映异构体、(D)-异构体、(L)-异构体，及其外消旋混合物和其他混合物，例如对映异构体或非对映体富集的混合物，所有这些混合物都属于本公开的范围之内。烷基等取代基中可存在另外的不对称碳原子。所有这些异构体以及它们的混合物，均包括在本公开的范围之内。本公开的含有不对称碳原子的化合物可以以光学活性纯的形式或外消旋形式被分离出来。光学活性纯的形式可以从外消旋混合物拆分，或通过使用手性原料或手性试剂合成。
可以通过的手性合成或手性试剂或者其他常规技术制备光学活性的(R)-和(S)-异构体以及D和L异构体。如果想得到本公开某化合物的一种对映体，可以通过不对称合成或者具有手性助剂的衍生作用来制备，其中将所得非对映体混合物分离，并且辅助基团裂开以提供纯的所需对映异构体。或者，当分子中含有碱性官能团(如氨基)或酸性官能团(如羧基)时，与适当的光学活性的酸或碱形成非对映异构体的盐，然后通过本领域所公知的常规方法进行非对映异构体拆分，然后回收得到纯的对映体。此外，对映异构体和非对映异构体的分离通常是通过使用色谱法完成的，所述色谱法采用手性固定相，并任选地与化学衍生法相结合(例如由胺生成氨基甲酸盐)。
本公开所述化合物的化学结构中，键
Figure PCTCN2022107479-appb-000030
表示未指定构型，即如果化学结构中存在手性异构体，键
Figure PCTCN2022107479-appb-000031
可以为
Figure PCTCN2022107479-appb-000032
或者同时包含
Figure PCTCN2022107479-appb-000033
Figure PCTCN2022107479-appb-000034
两种构型。键
Figure PCTCN2022107479-appb-000035
表示未指定构型，包括顺式(E)或反式(Z)构型。或者本公开所描述的
Figure PCTCN2022107479-appb-000036
是指双键，以该键键合的结构可为“顺式异构体”或“反式异构体”或者“顺式异构体和反式异构体以任何比例形成的混合物”，例如式E代表E-1、式E-2或两者以任何比例形成的混合物：
Figure PCTCN2022107479-appb-000037
本公开所述化合物的化学结构中，键
Figure PCTCN2022107479-appb-000038
并未指定构型，即可以为Z构型或E构型，或者同时包含两种构型。
本公开的化合物和中间体还可以以不同的互变异构体形式存在，并且所有这样的形式包含于本公开的范围内。术语“互变异构体”或“互变异构体形式”是指可经由低能垒互变的不同能量的结构异构体。例如，质子互变异构体(也称为质子转移互变异构体)包括经由质子迁移的互变，如酮-烯醇及亚胺-烯胺、内酰胺-内酰亚胺异构化。内酰胺-内酰亚胺平衡实例是在如下所示的A和B之间。
Figure PCTCN2022107479-appb-000039
本公开中的所有化合物可以被画成A型或B型。所有的互变异构形式在本公开的范围内。化合物的命名不排除任何互变异构体。
本公开还包括一些与本文中记载的那些相同的，但一个或多个原子被原子量或质量数不同于自然中通常发现的原子量或质量数的原子置换的同位素标记的本公开化合物。可结合到本公开化合物的同位素的实例包括氢、碳、氮、氧、磷、硫、氟、碘和氯的同位素，诸如分别为 2H、 3H、 11C、 13C、 14C、 13N、 15N、 15O、 17O、 18O、 31P、 32P、 35S、 18F、 123I、 125I和 36Cl等。
除另有说明，当一个位置被特别地指定为氘(D)时，该位置应理解为具有大于氘的天然丰度(其为0.015％)至少1000倍的丰度的氘(即，至少10％的氘掺入)。示例中化合物的具有大于氘的天然丰度可以是至少1000倍的丰度的氘、至少2000倍的丰度的氘、至少3000倍的丰度的氘、至少4000倍的丰度的氘、至少5000倍的丰度的氘、至少6000倍的丰度的氘或更高丰度的氘。本公开还包括各种氘化形式的式(I)化合物。与碳原子连接的各个可用的氢原子可独立地被氘原子替换。本领域技术人员能够参考相关文献合成氘化形式的式(I)化合物。在制备氘代形式的式(I)化合物时可使用市售的氘代起始物质，或它们可使用常规技术采用氘代试剂合成，氘代试剂包括但不限于氘代硼烷、三氘代硼烷四氢呋喃溶液、氘代氢化锂铝、氘代碘乙烷和氘代碘甲烷等。
“任选地”或“任选”是指意味着随后所描述的事件或环境可以但不必发生，该说明包括该事件或环境发生或不发生的场合。例如“任选的被卤素或者氰基取代的C 1-6烷基”是指卤素或者氰基可以但不必须存在，该说明包括烷基被卤素或者氰基取代的情形和烷基不被卤素和氰基取代的情形。
“药物组合物”表示含有一种或多种本文所述化合物或其生理学上可药用盐或前体药物与其他化学组分的混合物，以及其他组分例如生理学可药用的载体和赋形剂。药物组合物的目的是促进对生物体的给药，利于活性成分的吸收进而发挥生物活性。
“可药用赋形剂”包括但不限于任何已经被美国食品和药物管理局批准对于人类或家畜动物使用可接受的任何助剂、载体、赋形剂、助流剂、甜味剂、稀释 剂、防腐剂、染料/着色剂、增香剂、表面活性剂、润湿剂、分散剂、助悬剂、稳定剂、等渗剂、溶剂或乳化剂。
本公开中所述“有效量”或“有效治疗量”包含足以改善或预防医学病症的症状或病症的量。有效量还意指足以允许或促进诊断的量。用于特定患者或兽医学受试者的有效量可依据以下因素而变化：如待治疗的病症、患者的总体健康情况、给药的方法途径和剂量以及副作用严重性。有效量可以是避免显著副作用或毒性作用的最大剂量或给药方案。
术语“药物”是指细胞毒性药物或免疫调节剂。细胞毒性药物能在肿瘤细胞内具有较强破坏其正常生长的化学分子。细胞毒性药物原则上在足够高的浓度下都可以杀死肿瘤细胞，但是由于缺乏特异性，在杀伤肿瘤细胞的同时，也会导致正常细胞的凋亡，导致严重的副作用。该术语包括毒素，如细菌、真菌、植物或动物来源的小分子毒素或酶活性毒素，放射性同位素(例如At 211、I 131、I 125、Y 90、Re 186、Re 188、Sm 153、Bi 212、P 32和Lu的放射性同位素)，毒性药物，化疗药物，抗生素和核溶酶。免疫调节剂是免疫关卡分子的抑制剂。
术语“连接子”、“连接单元”、“接头单元”、“接头”或“连接片段”是指一端与配体连接而另一端与药物相连的化学结构片段或键，也可以连接其他接头后再与药物相连。
接头可以包含一种或多种接头构件。例示性的接头构件包括6-马来酰亚氨基己酰基(MC)、马来酰亚氨基丙酰基(MP)、缬氨酸-瓜氨酸(Val-Cit或vc)、丙氨酸-苯丙氨酸(ala-phe)、对氨基苄氧羰基(PAB)，及那些源自与接头试剂的偶联的：N-琥珀酰亚氨基4-(2-吡啶基硫代)戊酸酯(SPP)、N-琥珀酰亚氨基4-(N-马来酰亚氨基甲基)环己烷-1羧酸酯(SMCC，在本文中也称作MCC)和N-琥珀酰亚氨基(4-碘-乙酰基)氨基苯甲酸酯(SIAB)。接头可以包括拉伸单元、间隔单元、氨基酸单元和延伸单元。可以通过本领域已知方法合成，诸如US2005-0238649A1中所记载的。接头可以是便于在细胞中释放药物的“可切割接头”。例如，可使用酸不稳定接头(例如腙)、蛋白酶敏感(例如肽酶敏感)接头、光不稳定接头、二甲基接头、或含二硫化物接头(Chari等,Cancer Research 52:127-131(1992)；美国专利No.5,208,020)。
术语“拉伸单元”指一端通过碳原子与抗体共价连接而另一端与氨基酸单元、二硫化物部分、磺酰胺部分或非肽化学部分相连的化学结构片段。
术语“间隔单元”是一种双功能化合结构片段，可用于偶联氨基酸单元和细胞毒性药物最终形成抗体-药物偶联物，这种偶联方式可以将细胞毒性药物选择性的连接到氨基酸单元上。
术语“氨基酸”是指分子结构中含有氨基和羧基，并且氨基和羧基都直接连接在-CH-结构上的有机化合物。通式是H 2NCHRCOOH，R为H、取代或未取代烷基等。根据氨基连结在羧酸中碳原子的位置，可分为α、β、γ、δ、ε……-氨基酸。 在生物界中，构成天然蛋白质的氨基酸具有其特定的结构特点，即其氨基直接连接在α-碳原子上，即α-氨基酸，包括甘氨酸(Glycine)、丙氨酸(Alanine)、缬氨酸(Valine)、亮氨酸(Leucine)、异亮氨酸(Isoleucine)、苯丙氨酸(Phenylalanine)、色氨酸(Tryptophan)、酪氨酸(Tyrosine)、天冬氨酸(Aspartic acid)、组氨酸(Histidine)、天冬酰胺(Asparagine)、谷氨酸(Glutamic acid)、赖氨酸(Lysine)、谷氨酰胺(Glutamine)、甲硫氨酸(Methionine)、精氨酸(Arginine)、丝氨酸(Serine)、苏氨酸(Threonine)、半胱氨酸(Cysteine)、脯氨酸(Proline)等。非天然氨基酸如瓜氨酸。如本领域技术人员所公知的，非天然氨基酸并不构成天然蛋白质，因此也不参与本公开中抗体的合成。本公开所用氨基酸三字母代码和单字母代码如J.biol.chem,243,p3558(1968)中所述。
Figure PCTCN2022107479-appb-000040
Figure PCTCN2022107479-appb-000041
本公开中间隔单元为PAB，结构如对氨基苯甲氧羰基片段，其结构如式(VI)所示，连接在D上，
Figure PCTCN2022107479-appb-000042
接头组件包括但不限于：
MC＝6-马来酰亚氨基己酰基，结构如下：
Figure PCTCN2022107479-appb-000043
Val-Cit或“vc”＝缬氨酸-瓜氨酸(蛋白酶可切割接头中的例示二肽)
瓜氨酸＝2-氨基-5-脲基戊酸
Me-Val-Cit＝N-甲基-缬氨酸-瓜氨酸(其中接头肽键已经修饰以防止其受到组织蛋白酶B的切割)
MC(PEG) 6-OH＝马来酰亚氨基己酰基-聚乙二醇(可附着于抗体半胱氨酸)
SPP＝N-琥珀酰亚氨基4-(2-吡啶基硫代)戊酸酯
SPDP＝N-琥珀酰亚氨基3-(2-吡啶基二硫代)丙酸酯
SMCC＝琥珀酰亚氨基-4-(N-马来酰亚氨基甲基)环己烷-1-羧酸酯
IT＝亚氨基硫烷
PBS＝磷酸缓冲盐溶液。
术语“抗体-药物偶联物”，指配体通过稳定的连接单元与具有生物活性的药物相连。在本公开中“抗体-药物偶联物”(antibody drug conjugate，ADC)，指把单克隆抗体或者抗体片段通过稳定的连接单元与具有生物活性的毒性药物相连。
术语“载药量”可以表示为药物量和抗体量的比值，即ADC中每个抗体所偶联的药物的平均数量。载药量的范围可以是每个抗体(Ab)连接1-20个，优选1-10个细胞毒性药物(D)。在本公开的实施方式中，载药量表示为k，示例性的可以为1、2、3、4、5、6、7、8、9、10、11、12、13、14、15、16、17、18、19、20或任意两数值之间数值的均值。优选1-10，更优选1-8，或2-8，或2-7，或3-8，或3-7，或3-6，或4-7，或4-6，或4-5的均值。可用常规方法如UV/可见光光谱法、质谱、ELISA试验、单抗分子大小变异体测定法(CE-SDS)和HPLC特征鉴定偶联反应后每个ADC分子的药物平均数量。
本公开单抗分子大小变异体测定法(CE-SDS)可采用十二烷基硫酸钠毛细管电泳(CE-SDS)紫外检测方法，在还原和非还原条件下，依据分子量大小，按毛电泳法(2015年版《中国药典》0542)，定量测定重组单克隆抗体产品的纯度。
可以用以下非限制性方法控制抗体-药物偶联物的载量，包括：
(1)控制连接试剂和单抗的摩尔比，
(2)控制反应时间和温度，
(3)选择不同的反应试剂。
术语“抗体”指免疫球蛋白，是由两条相同的重链和两条相同的轻链通过链间二硫键连接而成的四肽链结构。免疫球蛋白重链恒定区的氨基酸组成和排列顺序不同，故其抗原性也不同。据此，可将免疫球蛋白分为五类，或称为免疫球蛋白的同种型，即IgM、IgD、IgG、IgA和IgE，其相应的重链分别为μ链、δ链、γ链、α链、和ε链。同一类Ig根据其铰链区氨基酸组成和重链二硫键的数目和位置的差别，又可分为不同的亚类，如IgG可分为IgG1、IgG2、IgG3、IgG4。轻链通过恒定区的不同分为κ链或λ链。五类Ig中每类Ig都可以有κ链或λ链。抗体重链和轻链靠近N端的约110个氨基酸的序列变化很大，为可变区(Fv区)；靠近C端的其余氨基酸序列相对稳定，为恒定区。可变区包括3个高变区(HVR)和4个序列相对保守的骨架区(FR)。3个高变区决定抗体的特异性，又称为互补性决定区(CDR)。每条轻链可变区(LCVR)和重链可变区(HCVR)由3个CDR区4个FR区组成，从氨基端到羧基端依次排列的顺序为：FR1，CDR1，FR2，CDR2，FR3，CDR3，FR4。轻链的3个CDR区指LCDR1、LCDR2、和LCDR3；重链的3个CDR区指HCDR1、HCDR2和HCDR3。
本公开的抗体包括鼠源抗体、嵌合抗体、人源化抗体和全人源抗体，优选人源化抗体和全人源抗体。
术语“鼠源抗体”在本公开中为根据本领域知识和技能用鼠制备抗体。制备时用特定抗原注射试验对象，然后分离表达具有所需序列或功能特性的抗体的杂交瘤。
术语“嵌合抗体(chimeric antibody)”，是将鼠源性抗体的可变区与人抗体的恒定区融合而成的抗体，可以减轻鼠源性抗体诱发的免疫应答反应。建立嵌合抗体，要先建立分泌鼠源性特异性单抗的杂交瘤，然后从鼠杂交瘤细胞中克隆可变区基因，再根据需要克隆人抗体的恒定区基因，将鼠可变区基因与人恒定区基因连接成嵌合基因后插入表达载体中，最后在真核系统或原核系统中表达嵌合抗体分子。
术语“人源化抗体(humanized antibody)”，也称为CDR移植抗体(CDR-grafted antibody)，是指将鼠的CDR序列移植到人的抗体可变区框架，即不同类型的人种系抗体框架序列中产生的抗体。可以克服嵌合抗体由于携带大量鼠蛋白成分，从而诱导的异源性反应。此类构架序列可以从包括种系抗体基因序列的公共DNA数据库或公开的参考文献获得。如人重链和轻链可变区基因的种系DNA序列可以在“VBase”人种系序列数据库(在因特网 www.mrccpe.com.ac.uk/vbase可获得)，以及在Kabat，E.A.等人，1991 Sequences of Proteins of Immunological Interest，第5版中找到。为避免免疫原性下降的同时，引起的活性下降，可对所述的人抗体可变区框架序列进行最少反向突变或回复突变，以保持活性。本公开的人源化抗体也包括进一步由噬菌体展示对CDR进行亲和力成熟后的人源化抗体。进一步描述参与人源化可使用小鼠抗体的方法的文献包括，例如Queen等，Proc.，Natl.Acad.Sci.USA，88，2869，1991和Winter及其同事的方法[Jones等，Nature，321，522(1986)，Riechmann，等，Nature，332，323-327(1988)，Verhoeyen，等，Science，239，1534(1988)]。
术语“全人源抗体”、“全人抗体”或“完全人源抗体”，也称“全人源单克隆抗体”，其抗体的可变区和恒定区都是人源的，去除免疫原性和毒副作用。单克隆抗体的发展经历了四个阶段，分别为：鼠源性单克隆抗体、嵌合性单克隆抗体、人源化单克隆抗体和全人源单克隆抗体。本公开为全人源单克隆抗体。全人抗体制备的相关技术主要有：人杂交瘤技术、EBV转化B淋巴细胞技术、噬菌体显示技术(phage display)、转基因小鼠抗体制备技术(transgenic mouse)和单个B细胞抗体制备技术等。
术语“抗原结合片段”是指抗体的保持特异性结合抗原的能力的一个或多个片段。已显示可利用全长抗体的片段来进行抗体的抗原结合功能。“抗原结合片段”中包含的结合片段的实例包括(i)Fab片段，由VL、VH、CL和CH1结构域组成的单价片段；(ii)F(ab') 2片段，包含通过铰链区上的二硫桥连接的两个Fab 片段的二价片段；(iii)由VH和CH1结构域组成的Fd片段；(iv)由抗体的单臂的VH和VL结构域组成的Fv片段；(v)单结构域或dAb片段(Ward等人,(1989)Nature341：544-546)，其由VH结构域组成；和(vi)分离的互补决定区(CDR)或(vii)可任选地通过合成的接头连接的两个或更多个分离的CDR的组合。此外，虽然Fv片段的两个结构域VL和VH由分开的基因编码，但可使用重组方法，通过合成的接头连接它们，从而使得其能够产生为其中VL和VH区配对形成单价分子的单个蛋白质链(称为单链Fv(scFv)；参见，例如，Bird等人(1988)Science242:423-426；和Huston等人(1988)Proc.Natl.Acad.Sci USA85:5879-5883)。此类单链抗体也意欲包括在术语抗体的“抗原结合片段”中。使用本领域技术人员已知的常规技术获得此类抗体片段，并且以与对于完整抗体的方式相同的方式就功用性筛选片段。可通过重组DNA技术或通过酶促或化学断裂完整免疫球蛋白来产生抗原结合部分。抗体可以是不同同种型的抗体，例如，IgG(例如，IgG1、IgG2、IgG3或IgG4亚型)、IgA1、IgA2、IgD、IgE或IgM抗体。
Fab是通过用蛋白酶木瓜蛋白酶(切割H链的224位的氨基酸残基)处理IgG抗体分子所获得的片段中的具有约50,000的分子量并具有抗原结合活性的抗体片段，其中H链N端侧的约一半和整个L链通过二硫键结合在一起。
F(ab')2是通过用酶胃蛋白酶消化IgG铰链区中两个二硫键的下方部分而获得的分子量为约100,000并具有抗原结合活性并包含在铰链位置相连的两个Fab区的抗体片段。
Fab'是通过切割上述F(ab')2的铰链区的二硫键而获得的分子量为约50,000并具有抗原结合活性的抗体片段。
此外，可以通过将编码抗体的Fab'片段的DNA插入到原核生物表达载体或真核生物表达载体中并将载体导入到原核生物或真核生物中以表达Fab'来生产所述Fab'。
术语“单链抗体”、“单链Fv”或“scFv”意指包含通过接头连接的抗体重链可变结构域(或区域；VH)和抗体轻链可变结构域(或区域；VL)的分子。此类scFv分子可具有一般结构：NH 2-VL-接头-VH-COOH或NH 2-VH-接头-VL-COOH。合适的现有技术接头由重复的GGGGS氨基酸序列或其变体组成，例如使用1-4个重复的变体(Holliger等人(1993)，Proc.Natl.Acad.Sci.USA90:6444-6448)。可用于本公开的其他接头由Alfthan等人(1995)，Protein Eng.8:725-731，Choi等人(2001)，Eur.J.Immuno l.31:94-106，Hu等人(1996)，Cancer Res.56:3055-3061，Kipriyanov等人(1999)，J.Mol.Biol.293:41-56和Roovers等人(2001)，Cancer Immunol.描述。
术语“CDR”是指抗体的可变结构域内主要促成抗原结合的6个高变区之一。所述6个CDR的最常用的定义之一由Kabat E.A.等人，(1991)Sequences of proteins of immunological interest.NIH Publication91-3242)提供。如本文中使用的， CDR的Kabat定义只应用于轻链可变结构域的CDR1、CDR2和CDR3(CDR L1、CDR L2、CDR L3或L1、L2、L3)，以及重链可变结构域的CDR2和CDR3(CDR H2、CDR H3或H2、H3)。通常，每个重链可变区中存在三个CDR(HCDR1、HCDR2、HCDR3)，每个轻链可变区中存在三个CDR(LCDR1、LCDR2、LCDR3)。可以使用各种公知方案中的任何一种来确定CDR的氨基酸序列边界，包括“Kabat”编号规则(参见Kabat等(1991)，“Sequences of Proteins of Immunological Interest”，第5版，Public Health Service，National Institutes of Health，Bethesda，MD)、“Chothia”编号规则(参见Al-Lazikani等人，(1997)JMB 273：927-948)和ImMunoGenTics(IMGT)编号规则(参见Lefranc M.P.，Immunologist，7，132-136(1999)；Lefranc，M.P.等，Dev.Comp.Immunol.，27，55-77(2003))等。例如，对于经典格式，遵循Kabat规则，所述重链可变域(VH)中的CDR氨基酸残基编号为31-35(HCDR1)、50-65(HCDR2)和95-102(HCDR3)；轻链可变域(VL)中的CDR氨基酸残基编号为24-34(LCDR1)、50-56(LCDR2)和89-97(LCDR3)。遵循Chothia规则，VH中的CDR氨基酸编号为26-32(HCDR1)、52-56(HCDR2)和95-102(HCDR3)；并且VL中的氨基酸残基编号为26-32(LCDR1)、50-52(LCDR2)和91-96(LCDR3)。通过组合Kabat和Chothia两者的CDR定义，CDR由人VH中的氨基酸残基26-35(HCDR1)、50-65(HCDR2)和95-102(HCDR3)和人VL中的氨基酸残基24-34(LCDR1)、50-56(LCDR2)和89-97(LCDR3)构成。遵循IMGT规则，VH中的CDR氨基酸残基编号大致为26-35(CDR1)、51-57(CDR2)和93-102(CDR3)，VL中的CDR氨基酸残基编号大致为27-32(CDR1)、50-52(CDR2)和89-97(CDR3)。遵循IMGT规则，抗体的CDR区可以使用程序IMGT/DomainGap Align确定。
术语“抗体框架”，是指可变结构域VL或VH的一部分，其用作该可变结构域的抗原结合环(CDR)的支架。从本质上讲，其是不具有CDR的可变结构域。
术语“表位”或“抗原决定簇”是指抗原上免疫球蛋白或抗体特异性结合的部位。表位通常以独特的空间构象包括至少3、4、5、6、7、8、9、10、11、12、13、14或15个连续或非连续的氨基酸(参见，例如，Epitope Mapping Protocols in Methods in Molecular B iology，第66卷，G.E.Morris，Ed.(1996))。
术语“特异性结合”、“选择性结合”、“选择性地结合”和“特异性地结合”是指抗体对预先确定的抗原上的表位的结合。通常，抗体以大约小于10 -7M，例如：大约小于10 -8M、10 -9M或10 -10M或更小的亲和力(KD)结合。
术语“核酸分子”是指DNA分子和RNA分子。核酸分子可以是单链或双链的，但优选是双链DNA。当将核酸与另一个核酸序列置于功能关系中时，核酸是“有效连接的”。例如，如果启动子或增强子影响编码序列的转录，那么启动子或增强子有效地连接至所述编码序列。
术语“载体”是指能够运输已与其连接的另一个核酸的核酸分子。在一个实 施方案中，载体是“质粒”，其是指可将另外的DNA区段连接至其中的环状双链DNA环。在另一个实施方案中，载体是病毒载体，其中可将另外的DNA区段连接至病毒基因组中。本文中公开的载体能够在已引入它们的宿主细胞中自主复制(例如，具有细菌的复制起点的细菌载体和附加型哺乳动物载体)或可在引入宿主细胞后整合入宿主细胞的基因组，从而随宿主基因组一起复制(例如，非附加型哺乳动物载体)。
现有技术中熟知生产和纯化抗体和抗原结合片段的方法，如冷泉港的抗体实验技术指南，5-8章和15章。抗原结合片段同样可以用常规方法制备。发明所述的抗体或抗原结合片段用基因工程方法在非人源的CDR区加上一个或多个人源FR区。人FR种系序列可以通过比对IMGT人类抗体可变区种系基因数据库和MOE软件，从ImMunoGeneTics(IMGT)的网站http://imgt.cines.fr得到，或者从免疫球蛋白杂志，2001ISBN012441351上获得。
术语“宿主细胞”是指已向其中引入了表达载体的细胞。宿主细胞可包括细菌、微生物、植物或动物细胞。易于转化的细菌包括肠杆菌科(enterobacteriaceae)的成员，例如大肠杆菌(Escherichia coli)或沙门氏菌(Salmonella)的菌株；芽孢杆菌科(Bacillaceae)例如枯草芽孢杆菌(Bacillus subtilis)；肺炎球菌(Pneumococcus)；链球菌(Streptococcus)和流感嗜血菌(Haemophilus influenzae)。适当的微生物包括酿酒酵母(Saccharomyces cerevisiae)和毕赤酵母(Pichia pastoris)。适当的动物宿主细胞系包括CHO(中国仓鼠卵巢细胞系)和NS0细胞。
本公开工程化的抗体或抗原结合片段可用常规方法制备和纯化。比如，编码重链和轻链的cDNA序列，可以克隆并重组至GS表达载体。重组的免疫球蛋白表达载体可以稳定地转染CHO细胞。作为一种更推荐的现有技术，哺乳动物类表达系统会导致抗体的糖基化，特别是在Fc区的高度保守N端位点。阳性的克隆在生物反应器的无血清培养基中扩大培养以生产抗体。分泌了抗体的培养液可以用常规技术纯化。比如，用含调整过的缓冲液的A或G Sepharose FF柱进行纯化。洗去非特异性结合的组分。再用PH梯度法洗脱结合的抗体，用SDS-PAGE检测抗体片段，收集。抗体可用常规方法进行过滤浓缩。可溶的混合物和多聚体，也可以用常规方法去除，比如分子筛、离子交换。得到的产物需立即冷冻，如-70℃，或者冻干。
氨基酸序列“同一性”指在比对氨基酸序列及必要时引入间隙，以达成最大序列同一性百分比，且不将任何保守性取代视为序列同一性的一部分，第一序列中与第二序列中的氨基酸残基同一的氨基酸残基的百分比。为测定氨基酸序列同一性百分比的目的，比对可以通过属于本领域技术的范围内的多种方式来实现，例如使用公开可得到的计算机软件，诸如BLAST、BLAST-2、ALIGN、ALIGN-2或Megalign(DNASTAR)软件。本领域技术人员可确定适用于测量比对的参数，包括在所比较的序列全长上达成最大比对所需的任何算法。
术语“肽”是指介于氨基酸和蛋白质之间的化合物片段，由2个或2个以上氨基酸分子通过肽键相互连接而成，是蛋白质的结构与功能片段，如激素、酶类等本质上都是肽。
术语“糖”是指由C、H、O三种元素组成的生物大分子，可分为单糖、二糖和多糖等。
术语“荧光探针”是指在紫外-可见-近红外区有特征荧光，并且其荧光性质(激发和发射波长、强度、寿命和偏振等)可随所处环境的性质，如极性、折射率、粘度等改变而灵敏地改变的一类荧光性分子，其与核酸(DNA或RNA)、蛋白质或其他大分子结构非共价相互作用而使一种或几种荧光性质发生改变，可用于研究大分子物质的性质和行为。
术语“烷基”指饱和脂肪族烃基团，其为包含1至20个碳原子的直链或支链基团，优选含有1至12个碳原子的烷基，更优选含有1至10个碳原子的烷基，最优选含有1至6个碳原子的烷基。非限制性实例包括甲基、乙基、正丙基、异丙基、正丁基、异丁基、叔丁基、正己基、1-乙基-2-甲基丙基，及其各种支链异构体等。更优选的是含有1至6个碳原子的低级烷基，非限制性实施例包括甲基、乙基、正丙基、异丙基、正丁基、异丁基、叔丁基、仲丁基、正戊基、1,1-二甲基丙基、1,2-二甲基丙基、2,2-二甲基丙基、1-乙基丙基、2-甲基丁基等。烷基可以是取代的或非取代的，当被取代时，取代基可以在任何可使用的连接点上被取代，所述取代基优选为一个或多个以下基团，其独立地选自烷基、烷氧基、卤素、氨基、氰基、硝基、羟基、羟烷基、环烷基、杂环基、芳基和杂芳基。
术语“杂烷基”指含有一个或多个选自N、O或S的杂原子的烷基，其中烷基如上所定义。
“一价基团”是指一个化合物从“形式上”消除一个单价的原子或基团。“亚基”则是指化合物从“形式上”消除两个单价或一个双价形成的原子或原子团。示例“烷基”是指由烷烃分子中去除1个氢原子后余下的部分，包括1至20个碳原子的直链和支链一价基团。含有1至6个碳原子的烷基，非限制性实施例包括甲基、乙基、正丙基、异丙基、正丁基、异丁基、叔丁基、仲丁基、正戊基、1,1-二甲基丙基、1,2-二甲基丙基、2,2-二甲基丙基及其各种支链异构体等。
术语“亚烷基”指饱和的直链或支链脂肪族烃基，其具有2个从母体烷的相同碳原子或两个不同的碳原子上除去两个氢原子所衍生的残基，其为包含1至20个碳原子的直链或支链基团，优选含有1至12个碳原子，更优选含有1至6个碳原子的亚烷基。亚烷基的非限制性实例包括但不限于亚甲基(-CH 2-)、1,1-亚乙基(-CH(CH 3)-)、1,2-亚乙基(-CH 2CH 2)-、1,1-亚丙基(-CH(CH 2CH 3)-)、1,2-亚丙基(-CH 2CH(CH 3)-)、1,3-亚丙基(-CH 2CH 2CH 2-)、1,4-亚丁基(-CH 2CH 2CH 2CH 2-)和1,5-亚丁基(-CH 2CH 2CH 2CH 2CH 2-)等。亚烷基可以是取代的或非取代的，当被取代时，取代基可以在任何可使用的连接点上被取代，所述取代基优选独立地任选选自卤 素、羟基、氰基、氨基、烷基、氯代烷基、烷氧基和环烷基中的一个或多个。同理，“亚烯基”如前所定义。
术语“烷氧基”指-O-(烷基)和-O-(非取代的环烷基)，其中烷基或环烷基的定义如上所述。烷氧基的非限制性实例包括：甲氧基、乙氧基、丙氧基、丁氧基、环丙氧基、环丁氧基、环戊氧基、环己氧基。烷氧基可以是任选取代的或非取代的，当被取代时，取代基优选为一个或多个以下基团，其独立地选自烷基、烯基、炔基、烷氧基、烷硫基、烷基氨基、卤素、巯基、羟基、硝基、氰基、环烷基、杂环烷基、芳基、杂芳基、环烷氧基、杂环烷氧基、环烷硫基、杂环烷硫基。
术语“环烷基”指饱和或部分不饱和单环或多环环状烃取代基，环烷基环包含3至20个碳原子，优选包含3至12个碳原子，更优选包含3至10个碳原子，最优选包含3至8个碳原子。单环环烷基的非限制性实例包括环丙基、环丁基、环戊基、环戊烯基、环己基、环己烯基、环己二烯基、环庚基、环庚三烯基、环辛基等；多环环烷基包括螺环、稠环和桥环的环烷基。
术语“杂环烷基”指饱和或部分不饱和单环或多环环状烃取代基，其包含3至20个环原子，其中一个或多个环原子为选自氮、氧或S(O) m(其中m是整数0至2)的杂原子，但不包括-O-O-、-O-S-或-S-S-的环部分，其余环原子为碳。优选包含3至12个环原子，其中1至4个是杂原子；更优选环烷基环包含3至10个环原子。单环杂环烷基的非限制性实例包括吡咯烷基、哌啶基、哌嗪基、吗啉基、硫代吗啉基、高哌嗪基等。多环杂环烷基包括螺环、稠环和桥环的杂环烷基。
术语“螺杂环烷基”指5至20元的单环之间共用一个原子(称螺原子)的多环杂环烷基团，其中一个或多个环原子为选自氮、氧或S(O) m(其中m是整数0至2)的杂原子，其余环原子为碳。其可以含有一个或多个双键，但没有一个环具有完全共轭的π电子系统。优选为6至14元，更优选为7至10元。根据环与环之间共用螺原子的数目将螺杂环烷基分为单螺杂环烷基、双螺杂环烷基或多螺杂环烷基，优选为单螺杂环烷基和双螺杂环烷基。更优选为4元/4元、4元/5元、4元/6元、5元/5元或5元/6元单螺杂环烷基。螺杂环烷基的非限制性实例包括：
Figure PCTCN2022107479-appb-000044
术语“稠杂环烷基”指5至20元，系统中的每个环与体系中的其他环共享毗邻的一对原子的多环杂环烷基团，一个或多个环可以含有一个或多个双键，但没有一个环具有完全共轭的π电子系统，其中一个或多个环原子为选自氮、氧或S(O) m(其中m是整数0至2)的杂原子，其余环原子为碳。优选为6至14元，更优选为7至10元。根据组成环的数目可以分为双环、三环、四环或多环稠杂环烷基， 优选为双环或三环，更优选为5元/5元或5元/6元双环稠杂环烷基。稠杂环烷基的非限制性实例包括：
Figure PCTCN2022107479-appb-000045
术语“桥杂环烷基”指5至14元，任意两个环共用两个不直接连接的原子的多环杂环烷基团，其可以含有一个或多个双键，但没有一个环具有完全共轭的π电子系统，其中一个或多个环原子为选自氮、氧或S(O) m(其中m是整数0至2)的杂原子，其余环原子为碳。优选为6至14元，更优选为7至10元。根据组成环的数目可以分为双环、三环、四环或多环桥杂环烷基，优选为双环、三环或四环，更优选为双环或三环。桥杂环烷基的非限制性实例包括：
Figure PCTCN2022107479-appb-000046
所述杂环烷基环可以稠合于芳基、杂芳基或环烷基环上，其中与母体结构连接在一起的环为杂环烷基，其非限制性实例包括：
Figure PCTCN2022107479-appb-000047
等。
杂环烷基可以是任选取代的或非取代的，当被取代时，取代基优选为一个或多个以下基团，其独立地选自烷基、烯基、炔基、烷氧基、烷硫基、烷基氨基、卤素、巯基、羟基、硝基、氰基、环烷基、杂环烷基、芳基、杂芳基、环烷氧基、杂环烷氧基、环烷硫基、杂环烷硫基、氧代基。
术语“芳基”指具有共轭的π电子体系的6至14元全碳单环或稠合多环(也就是共享毗邻碳原子对的环)基团，优选为6至10元，例如苯基和萘基，优选苯基。所述芳基环可以稠合于杂芳基、杂环烷基或环烷基环上，其中与母体结构连接在一起的环为芳基环，其非限制性实例包括：
Figure PCTCN2022107479-appb-000048
芳基可以是取代的或非取代的，当被取代时，取代基优选为一个或多个以下基团，其独立地选自烷基、烯基、炔基、烷氧基、烷硫基、烷基氨基、卤素、巯基、羟基、硝基、氰基、环烷基、杂环烷基、芳基、杂芳基、环烷氧基、杂环烷氧基、环烷硫基、杂环烷硫基。
术语“杂芳基”指包含1至4个杂原子、5至14个环原子的杂芳族体系，其中杂原子选自氧、硫和氮。杂芳基优选为5至10元，更优选为5元或6元，例如呋喃基、噻吩基、吡啶基、吡咯基、N-烷基吡咯基、嘧啶基、吡嗪基、咪唑基、四唑基等。所述杂芳基环可以稠合于芳基、杂环烷基或环烷基环上，其中与母体结构连接在一起的环为杂芳基环，其非限制性实例包括：
Figure PCTCN2022107479-appb-000049
杂芳基可以是任选取代的或非取代的，当被取代时，取代基优选为一个或多个以下基团，其独立地选自烷基、烯基、炔基、烷氧基、烷硫基、烷基氨基、卤素、巯基、羟基、硝基、氰基、环烷基、杂环烷基、芳基、杂芳基、环烷氧基、杂环烷氧基、环烷硫基、杂环烷硫基。
术语“氨基杂环烷基”指杂环烷基被一个或多个氨基取代，优选被一个氨基取代，其中杂环烷基如上所定义，其中“氨基”指-NH 2。本公开的代表性实施例如下：
Figure PCTCN2022107479-appb-000050
术语“杂环烷基氨基”指氨基被一个或多个杂环烷基取代，优选被一个杂环烷基取代，其中氨基如上所定义，其中杂环烷基如上所定义。本公开的代表性实施例如下：
Figure PCTCN2022107479-appb-000051
术语“环烷基氨基”指氨基被一个或多个环烷基取代，优选被一个环烷基取代，其中氨基如上所定义，其中环烷基如上所定义。本公开的代表性实施例如下：
Figure PCTCN2022107479-appb-000052
术语“环烷基烷基”指烷基被一个或多个环烷基取代，优选被一个环烷基取代，其中烷基如上所定义，其中环烷基如上所定义。
术语“卤代烷基”指烷基被一个或多个卤素取代，其中烷基如上所定义。
术语“氘代烷基”指烷基被一个或多个氘原子取代，其中烷基如上所定义。
术语“羟基”指-OH基团。
术语“卤素”指氟、氯、溴或碘。
术语“氨基”指-NH 2。
术语“硝基”指-NO 2。
化学式中简称“Me”为甲基。
“任选”或“任选地”意味着随后所描述的事件或环境可以但不必发生，该说明包括该事件或环境发生或不发生地场合。例如，“任选被烷基取代的杂环烷基团”意味着烷基可以但不必须存在，该说明包括杂环烷基团被烷基取代的情形和杂环烷基团不被烷基取代的情形。
“取代的”指基团中的一个或多个氢原子，优选为最多5个，更优选为1至3个氢原子彼此独立地被相应数目的取代基取代。不言而喻，取代基仅处在它们的可能的化学位置，本领域技术人员能够在不付出过多努力的情况下确定(通过实验或理论)可能或不可能的取代。例如，具有游离氢的氨基或羟基与具有不饱和(如烯属)键的碳原子结合时可能是不稳定的。
术语“药学上可接受的盐”或“可药用盐”是指本公开抗体-药物偶联物的盐，或本公开中所述的化合物的盐，这类盐用于哺乳动物体内时具有安全性和有效性，且具有应有的生物活性。本公开抗体-药物偶联物至少含有一个氨基，因此可以与酸形成盐，可药用盐的非限制性实例包括：盐酸盐。
术语“溶剂合物”指本公开的配体-药物偶联化合物与一种或多种溶剂分子形成可药用的溶剂合物，溶剂分子的非限制性实例包括水、乙醇、乙腈、异丙醇、DMSO、乙酸乙酯。
术语“药物载体”用于本公开的药物，是指能改变药物进入人体的方式和在体内的分布、控制药物的释放速度并将药物输送到靶向器官的体系。药物载体释 放和靶向系统能够减少药物降解及损失，降低副作用，提高生物利用度。如可作为载体的高分子表面活性剂由于其独特的两亲性结构，可以进行自组装，形成各种形式的聚集体，优选的实例如胶束、微乳液、凝胶、液晶、囊泡等。这些聚集体具有包载药物分子的能力，同时又对膜有良好的渗透性，可以作为优良的药物载体。
术语“赋形剂”是在药物制剂中除主药以外的附加物，也可称为辅料。如片剂中的粘合剂、填充剂、崩解剂、润滑剂；半固体制剂软膏剂、霜剂中的基质部分；液体制剂中的防腐剂、抗氧剂、矫味剂、芳香剂、助溶剂、乳化剂、增溶剂、渗透压调节剂、着色剂等均可称为赋形剂。
术语“稀释剂”又称填充剂，其主要用途是增加片剂的重量和体积。稀释剂的加入不仅保证一定的体积大小，而且减少主要成分的剂量偏差，改善药物的压缩成型性等。当片剂的药物含有油性组分时，需加入吸收剂吸收油性物，使保持“干燥”状态，以利于制成片剂。
“结合HER2的异二聚体结合位点的”HER2抗体结合结构域II中的残基(且任选还结合HER2的胞外域以外的其它结构域，诸如结构域I和III中的残基)，且至少在一定程度上能在空间上阻碍HER2-EGFR、HER2-HER3或HER2-HER4异二聚体的形成。Franklin et al.，Cancer Cell 5：317-328(2004)表征了存放在RCSB蛋白质数据库(ID Code IS78)的HER2-Pertuzumab晶体结构，举例说明了结合HER2的异二聚体结合位点的示例性抗体。
“结合HER2结构域II的”抗体结合结构域II中的残基和任选HER2的其它结构域，诸如结构域I和III中的残基。优选的是，结合结构域II的抗体结合HER2结构域I、II和III之间的连接处。
在本文中，“Pertuzumab”指包含分别在SEQ ID No.1和2中的轻链和重链可变区氨基酸序列的抗体。若Pertuzumab是完整抗体，则它优选包含分别在SEQ ID No.3和4中的轻链和重链氨基酸序列。“Pertuzumab”指包含分别在SEQ ID No.1和2中的轻链和重链可变区氨基酸序列的抗体。本公开“Trastuzumab”是包含分别在SEQ ID No.5和6中的轻链和重链氨基酸序列。制备方法参见WO2006033700并将相关内容引入本文以示说明。
附图说明
图1为N87/16-8皮下移植瘤模型小鼠肿瘤体积变化图。
图2为N87/16-8皮下移植瘤模型小鼠体重变化图。
图3为JIMIT-1皮下移植瘤模型小鼠肿瘤体积变化图。
图4为JIMIT-1皮下移植瘤模型小鼠体重变化图。
具体实施方式
以下结合实施例进一步描述本公开，但这些实施例并非限制本公开的范围。
本公开实施例中未注明具体条件的实验方法，通常按照常规条件，或按照原料或商品制造厂商所建议的条件。未注明具体来源的试剂，为市场购买的常规试剂。
化合物的结构是通过核磁共振(NMR)或/和质谱(MS)来确定的。NMR位移(δ)以10 -6(ppm)的单位给出。NMR的测定是用Bruker AVANCE-400核磁仪，测定溶剂为氘代二甲基亚砜(DMSO-d 6)、氘代氯仿(CDCl 3)、氘代甲醇(CD 3OD)，内标为四甲基硅烷(TMS)。
MS的测定用Agilent 1200/1290 DAD-6110/6120 Quadrupole MS液质联用仪(生产商：Agilent，MS型号：6110/6120 Quadrupole MS)。
waters ACQuity UPLC-QD/SQD(生产商：waters，MS型号：waters ACQuity Qda Detector/waters SQ Detector)THERMO Ultimate 3000-Q Exactive(生产商：THERMO，MS型号：THERMO Q Exactive)
高效液相色谱法(HPLC)分析使用Agilent HPLC 1200DAD、Agilent HPLC 1200VWD和Waters HPLC e2695-2489高压液相色谱仪。
手性HPLC分析测定使用Agilent 1260 DAD高效液相色谱仪。
高效液相制备使用Waters 2545-2767、Waters 2767-SQ Detecor2、Shimadzu LC-20AP和Gilson GX-281制备型色谱仪。
手性制备使用Shimadzu LC-20AP制备型色谱仪。
CombiFlash快速制备仪使用Combiflash Rf200(TELEDYNE ISCO)。
薄层层析硅胶板使用烟台黄海HSGF254或青岛GF254硅胶板，薄层色谱法(TLC)使用的硅胶板采用的规格是0.15mm至0.2mm，薄层层析分离纯化产品采用的规格是0.4mm至0.5mm。
硅胶柱色谱法一般使用烟台黄海硅胶200至300目硅胶为载体。
本发明的已知的起始原料可以采用或按照本领域已知的方法来合成，或可购买自ABCR GmbH&Co.KG，Acros Organics，Aldrich Chemical Company，韶远化学科技(Accela ChemBio Inc)、达瑞化学品等公司。
实施例中无特殊说明，反应能够均在氩气氛或氮气氛下进行。
氩气氛或氮气氛是指反应瓶连接一个约1L容积的氩气或氮气气球。
氢气氛是指反应瓶连接一个约1L容积的氢气气球。
加压氢化反应使用Parr 3916EKX型氢化仪和清蓝QL-500型氢气发生器或HC2-SS型氢化仪。
氢化反应通常抽真空，充入氢气，反复操作3次。
微波反应使用CEM Discover-S 908860型微波反应器。
实施例中无特殊说明，溶液是指水溶液。
实施例中无特殊说明，反应的温度为室温，为20℃至30℃。
纯化化合物采用的柱层析的洗脱剂的体系和薄层色谱法的展开剂的体系包括：A：二氯甲烷和异丙醇体系，B：二氯甲烷和甲醇体系，C：石油醚和乙酸乙酯体系，溶剂的体积比根据化合物的极性不同而进行调节，也可以加入少量的三乙胺和酸性或碱性试剂等进行调节。
实施例1
Figure PCTCN2022107479-appb-000053
步骤1：化合物1b的制备
冰水浴下，将化合物1a(艾日布林，参照ZL201010236637.2方法制备获得)(72.91mg，0.1mmol)溶于10mL的四氢呋喃中，加入Fmoc-OSu(芴甲氧羰酰琥珀酰亚胺，41mg，0.12mmol)，然后在室温搅拌至反应完全。减压浓缩得粗品，直接用于下一步反应。
步骤2：化合物1c的制备
将上步所得化合物1b的粗品溶于10mL无水乙醚中，加入氧化银(34.8mg，0.15mmol)，接着加入碘甲烷(28.4mg,0.2mmol)，然后于室温搅拌至反应完全，过滤，然后减压浓缩得粗品，直接进行下一步反应。
步骤3：化合物1的制备
将上步所得化合物1c粗品溶于10mL的四氢呋喃中，加入2mL的二乙胺，然后在室温搅拌至反应完全，减压浓缩得粗品，经硅胶柱层析色谱法(洗脱剂：二氯甲烷/乙酸乙酯/石油醚)纯化，得3mg目标产物化合物1。
LC/MS(ESI)：m/z 744.2[M+H] +。
Figure PCTCN2022107479-appb-000054
冰水浴下，将4a(50mg,0.08mmol，参照WO2017151979中方法制备)溶解到1.5mL的N,N-二甲基甲酰胺中，然后加入DIPEA(N,N-二异丙基乙胺，18mg,0.14mmol)，接着加入二(对硝基苯)碳酸酯(49mg,0.16mmol)，然后在室温下搅拌10加入20mL甲基叔丁基醚，搅拌20分钟，过滤，干燥得到固体36mg，LC/MS(ESI):m/z 784.1[M+H] +。
Figure PCTCN2022107479-appb-000055
将化合物1(13.5mg,0.018mmol)溶于1.5mL的DMF中，加入DIPEA(7mg,0.054mmol)，然后分批加入化合物4b(18mg,1.3mmol)，搅拌至反应基本完全，浓缩得粗品，经HPLC制备分离得6.5mg化合物L-1，纯度96.95％，LC/MS(ESI):m/z 1388.3[M+H] +。
实施例2 ADC-001
N-((2R,10S)-10-苄基-2-环丙基-1-(((1S,9S)-9-乙基-5-氟-9-羟基-4-甲基-10,13-二氧代-2,3,9,10,13,15-六氢-1H,12H-苯并[de]吡喃并[3',4':6,7]吲哚嗪并[1,2-b]喹啉-1-基)氨基)-1,6,9,12,15-五氧代-3-氧杂-5,8,11,14-四氮杂十六-16-基)-6-(2,5-二氧代-2,5-二氢-1H-吡咯-1-基)己酰胺L-2A
N-((2S,10S)-10-苄基-2-环丙基-1-(((1S,9S)-9-乙基-5-氟-9-羟基-4-甲基-10,13-二氧代-2,3,9,10,13,15-六氢-1H,12H-苯并[de]吡喃并[3',4':6,7]吲哚嗪并[1,2-b]喹啉-1-基)氨基)-1,6,9,12,15-五氧代-3-氧杂-5,8,11,14-四氮杂十六-16-基)-6-(2,5-二氧代-2,5-二氢-1H-吡咯-1-基)己酰胺L-2B
Figure PCTCN2022107479-appb-000056
第一步
2-环丙基-2-羟基乙酸苄酯1b
将1a(1.3g，11.2mmol；采用专利申请“WO2013/106717”公开的方法制备而得)溶于50mL乙腈中，依次加入碳酸钾(6.18g，44.8mmol)，溴化苄(1.33mL，11.2mmol)和四丁基碘化铵(413mg，1.1mmol)。将反应液室温搅拌48小时，通过硅藻土过滤，滤饼用乙酸乙酯(10ml)淋洗，合并滤液减压浓缩，用硅胶柱色谱法以展开剂体系C纯化所得残余物，得到标题产物1b(2g，产率：86.9％)。
第二步
10-环丙基-1-(9H-芴-9-基)-3,6-二氧代-2,9-二氧杂-4,7-二氮杂十一-11-酸苄酯1d
将1b(120.9mg,0.586mmol)和1c(180mg，0.489mmol)加入反应瓶，加入4mL四氢呋喃，氩气置换三次，冰水浴降温至0-5℃，加入叔丁醇钾(109mg，0.98mmol)，撤去冰浴，升至室温搅拌40分钟，加入10mL冰水，用乙酸乙酯(20mL×2)和氯仿(10mL×5)萃取，合并有机相并浓缩。所得残余物溶于4mL二氧六环中，加入2mL水，加入碳酸氢钠(49.2mg，0.586mmol)和氯甲酸-9-芴甲酯(126mg，0.49mmol)，室温搅拌2小时。加入20mL水，用乙酸乙酯(10mL×3)萃取，有机相用饱和氯化钠溶液(20mL)洗涤，无水硫酸钠干燥，过滤，滤液减压浓缩。用硅胶柱色谱法以展开剂体系C纯化所得残余物，得到标题产物1d(48mg，产率：19％)。
MS m/z(ESI):515.0[M+1]。
第三步
10-环丙基-1-(9H-芴-9-基)-3,6-二氧代-2,9-二氧杂-4,7-二氮杂十一-11-酸1e
将1d(20mg，0.038mmol)溶于4.5mL四氢呋喃和乙酸乙酯(V:V＝2:1)混合溶剂中，加入钯碳(12mg，含量10％，干型)，氢气置换三次，室温搅拌反应1小时。反应液用硅藻土过滤，滤饼用乙酸乙酯淋洗，滤液浓缩，得到粗品标题产物1e(13mg)，产品不经纯化直接进行下一步反应。
MS m/z(ESI):424.9[M+1]。
第四步
(9H-芴-9-基)甲基(2-(((1-环丙基-2-(((1S,9S)-9-乙基-5-氟-9-羟基-4-甲基-10,13-二氧代-2,3,9,10,13,15-六氢-1H,12H-苯并[de]吡喃并[3',4':6,7]吲哚嗪并[1,2-b]喹啉-1-基)氨基)-2-氧代乙氧基)甲基)氨基)-2-氧代乙基)氨基甲酸酯1g
将1f(10mg，18.8μmol)加入反应瓶，加入1mL N,N-二甲基甲酰胺，氩气置换三次，冰水浴降温至0-5℃，滴加一滴三乙胺，加入粗品9c(13mg，30.6μmol)，加入4-(4,6-二甲氧基-1,3,5-三嗪-2-基)-4-甲基氯化吗啉盐(16.9mg，61.2μmol)，冰浴搅拌反应40分钟。加入10mL水，用乙酸乙酯(10mL×3)萃取，合并有机相。有机相用饱和氯化钠溶液(10mL×2)洗涤，有机相用无水硫酸钠干燥，过滤，滤液减压浓缩。用薄层层析以展开剂体系B纯化所得残余物，得到标题产物1g(19mg，产率：73.6％)。
MS m/z(ESI):842.1[M+1]。
第五步
2-((2-氨基乙酰氨基)甲氧基)-2-环丙基-N-((1S,9S)-9-乙基-5-氟-9-羟基-4-甲基-10,13-二氧代-2,3,9,10,13,15-六氢-1H,12H-苯并[de]吡喃并[3',4':6,7]吲哚嗪并[1,2-b]喹啉-1-基)乙酰胺1h
将1g(19mg，22.6μmol)溶于2mL二氯甲烷中，加入1mL二乙胺，室温搅拌2小时。反应液减压浓缩，加入1mL甲苯并减压浓缩，重复两次。往残余物中加入3mL正己烷打浆，静置后倾倒出上层清液，保留固体。将固体残余物减压浓 缩，油泵拉干得到粗品标题产物1h(17mg)，产品不经纯化直接用于下一步反应。
MS m/z(ESI):638.0[M+18]。
第六步
N-((2R,10S)-10-苄基-2-环丙基-1-(((1S,9S)-9-乙基-5-氟-9-羟基-4-甲基-10,13-二氧代-2,3,9,10,13,15-六氢-1H,12H-苯并[de]吡喃并[3',4':6,7]吲哚嗪并[1,2-b]喹啉-1-基)氨基)-1,6,9,12,15-五氧代-3-氧杂-5,8,11,14-四氮杂十六-16-基)-6-(2,5-二氧代-2,5-二氢-1H-吡咯-1-基)己酰胺9-A
N-((2S,10S)-10-苄基-2-环丙基-1-(((1S,9S)-9-乙基-5-氟-9-羟基-4-甲基-10,13-二氧代-2,3,9,10,13,15-六氢-1H,12H-苯并[de]吡喃并[3',4':6,7]吲哚嗪并[1,2-b]喹啉-1-基)氨基)-1,6,9,12,15-五氧代-3-氧杂-5,8,11,14-四氮杂十六-16-基)-6-(2,5-二氧代-2,5-二氢-1H-吡咯-1-基)己酰胺9-B
将粗品1h(13.9mg，22.4μmol)溶于0.6mL N,N-二甲基甲酰胺，氩气置换三次，冰水浴降温至0-5℃，加入1l(21.2mg，44.8μmol)的0.3mL N,N-二甲基甲酰胺溶液，加入4-(4,6-二甲氧基-1,3,5-三嗪-2-基)-4-甲基氯化吗啉盐(18.5mg，67.3μmol)，冰浴搅拌反应10分钟，撤去冰浴，升至室温搅拌1小时，反应生成化合物L-2。反应液进行高效液相色谱法纯化(分离条件：色谱柱：XBridge Prep C18 OBD 5um 19*250mm；流动相:A-水(10mmol NH 4OAc)：B-乙腈，梯度洗脱，流速：18mL/min)，收集其相应组分，减压浓缩，得到标题产物L-2A：2.4mg，L-2B：1.7mg)。
MS m/z(ESI):1074.4[M+1]。
化合物L-2A和L-2B中保留时间较短者：
UPLC分析:保留时间1.14分钟，纯度：85％(色谱柱：ACQUITY UPLC BEHC18 1.7um 2.1*50mm，流动相：A-水(5mmol NH 4OAc),B-乙腈)。
1H NMR(400MHz,DMSO-d 6):δ8.60(t,1H),8.51-8.49(d,1H),8.32-8.24(m,1H),8.13-8.02(m,2H),8.02-7.96(m,1H),7.82-7.75(m,1H),7.31(s,1H),7.26-7.15(m,4H),6.99(s,1H),6.55-6.48(m,1H),5.65-5.54(m,1H),5.41(s,2H),5.35-5.15(m,3H),4.74-4.62(m,1H),4.54-4.40(m,2H),3.76-3.64(m，4H),3.62-3.48(m,2H),3.20-3.07(m,2H),3.04-2.94(m,1H),2.80-2.62(m,1H),2.45-2.30(m,3H),2.25-2.15(m,2H),2.15-2.04(m,2H),1.93-1.78(m,2H),1.52-1.39(m,3H),1.34-1.12(m,5H),0.87(t,3H),0.64-0.38(m,4H)。
化合物L-2A和L-2B中保留时间较长者：
UPLC分析:保留时间1.16分钟，纯度：89％(色谱柱：ACQUITY UPLC BEHC18 1.7um 2.1*50mm，流动相：A-水(5mmol NH 4OAc),B-乙腈)。
1H NMR(400MHz,DMSO-d 6):δ8.68-8.60(m,1H),8.58-8.50(m,1H),8.32-8.24(m,1H),8.13-8.02(m,2H),8.02-7.94(m,1H),7.82-7.75(m,1H),7.31(s,1H),7.26-7.13(m,3H),6.99(s,1H),6.55-6.48(m,1H),5.60-5.50(m,1H),5.41(s,2H),5.35-5.15(m,2H),4.78-4.68(m,1H),4.60-4.40(m,2H),3.76-3.58(m,4H),3.58-3.48(m,1H),3.20-3.10(m,2H),3.08-2.97(m,2H),2.80-2.72(m,2H),2.45-2.30(m,3H), 2.25-2.13(m,2H),2.13-2.04(m,2H),2.03-1.94(m,2H),1.91-1.78(m,2H),1.52-1.39(m,3H),1.34-1.12(m,4H),0.91-0.79(m,3H),0.53-0.34(m,4H)。
Figure PCTCN2022107479-appb-000057
在37℃条件下，向抗体Pertuzumab的PBS缓冲水溶液(pH＝6.5的0.05M的PBS缓冲水溶液；10.0mg/mL，1.50mL，101nmol)加入配置好的的三(2-羧乙基)膦盐酸盐(TCEP-HCl)的水溶液(10mM，16.2uL，162nmol)，置于水浴振荡器，于37℃下振荡反应3小时，停止反应。将反应液用水浴降温至25℃。
将化合物L-2A和L-2B中保留时间短者(0.87mg，810nmol)溶解于66uL二甲亚砜中，加入到上述反应液中，置于水浴振荡器，于25℃下振荡反应3小时，停止反应。将反应液用Sephadex G25凝胶柱脱盐纯化(洗脱相：pH＝6.5的0.05M的PBS缓冲水溶液，含0.001M的EDTA)，得到标题产物的PBS缓冲液(1.16mg/mL，12.0mL)，于4℃冷藏储存。
RP-HPLC计算平均值：n＝2.67。
实施例3.ADC-002
Figure PCTCN2022107479-appb-000058
在37℃条件下，向抗体Pertuzumab的PBS缓冲水溶液(pH＝6.5的0.05M的PBS缓冲水溶液；10.0mg/mL，1.50mL，101nmol)加入配置好的的三(2-羧乙基)膦盐酸盐(TCEP-HCl)的水溶液(10mM，28.4uL，284nmol)，置于水浴振荡器，于37℃下振荡反应3小时，停止反应。将反应液用水浴降温至25℃。
将化合物L-2A和L-2B中保留时间短者(1.09mg，1015nmol)溶解于84uL二甲亚砜中，加入到上述反应液中，置于水浴振荡器，于25℃下振荡反应3小时， 停止反应。将反应液用Sephadex G25凝胶柱脱盐纯化(洗脱相：pH＝6.5的0.05M的PBS缓冲水溶液，含0.001M的EDTA)，得到标题产物的PBS缓冲液(1.06mg/mL，12.0mL)，于4℃冷藏储存。
RP-HPLC计算平均值：n＝4.51。
实施例4 ADC-003
Figure PCTCN2022107479-appb-000059
在37℃条件下，向抗体Pertuzumab的PBS缓冲水溶液(pH＝6.5的0.05M的PBS缓冲水溶液；10.0mg/mL，1.43mL，97nmol)加入配置好的的三(2-羧乙基)膦盐酸盐(TCEP-HCl)的水溶液(10mM，15.5uL，155nmol)，置于水浴振荡器，于37℃下振荡反应3小时，停止反应。将反应液用水浴降温至25℃。
将化合物L-1(1.07mg，771nmol)溶解于50uL二甲亚砜中，加入到上述反应液中，置于水浴振荡器，于25℃下振荡反应3小时，停止反应。将反应液用Sephadex G25凝胶柱脱盐纯化(洗脱相：pH＝6.5的0.05M的PBS缓冲水溶液，含0.001M的EDTA)，得到标题产物的PBS缓冲液(1.21mg/mL，10.8mL)，于4℃冷藏储存。
CE-SDS计算平均值：n＝2.04。
实施例5 ADC-004
Figure PCTCN2022107479-appb-000060
在37℃条件下，向抗体Pertuzumab的PBS缓冲水溶液(pH＝6.5的0.05M的PBS缓冲水溶液；10.0mg/mL，1.43mL，97nmol)加入配置好的的三(2-羧乙基)膦盐酸盐(TCEP-HCl)的水溶液(10mM，24.2uL，242nmol)，置于水浴振荡器，于37℃下振荡反应3小时，停止反应。将反应液用水浴降温至25℃。
将化合物L-1(1.34mg，965nmol)溶解于60uL二甲亚砜中，加入到上述反应液中，置于水浴振荡器，于25℃下振荡反应3小时，停止反应。将反应液用Sephadex G25凝胶柱脱盐纯化(洗脱相：pH＝6.5的0.05M的PBS缓冲水溶液，含0.001M的EDTA)，得到标题产物的PBS缓冲液(1.24mg/mL，9.8mL)，于4℃冷藏储存。
CE-SDS计算平均值：n＝3.17。
实施例6 ADC-005
Figure PCTCN2022107479-appb-000061
参照实施例3方法，利用化合物L-2A和L-2B中保留时间长者与曲妥珠单抗(参照WO2006033700方法制备获得)为起始物料，制得目标产物的PBS缓冲液(1.24mg/mL，9.8mL)，于4℃冷藏储存。
CE-SDS计算平均值：n＝6。
测试例1：对体外培养人乳腺癌BT-474和人胃癌NCI-N87,NCI-N87/16-8,NCI-N87/8-2细胞增殖的抑制作用
1.1药物信息
序列 药品代号 浓度％ 纯度％
1 ADC-001 1.16 96.06
2 ADC002 1.06 95.13
3 ADC-003 1.21 98.18
4 ADC-004 1.24 97.57
5 ADC-005 5 /
6 kadcyla 10 /
注：以上样品由上海恒瑞有限公司提供。其中帕妥珠单抗按照WO2006033700中类似方法制备获得；kadcyla：曲妥珠单抗-美坦新偶联物。
1.2受试细胞
NCI-N87和BT-474细胞购自American Type Culture Collection(ATCC)。T-DM1长期作用NCI-N87诱导出的T-DM1耐药的NCI-N87/16-8和NCI-N87/8-2细胞由本实验室构建。细胞用含10％胎牛血清(FBS)的RPMI 1640/DMEM(1：1)培养液培养。
1.3仪器及试剂
RPMI 1640和DMEM购自Gibco BRL公司；FBS购自Gibco公司；磺酰罗丹明B(SRB)购自Sigma公司。
酶标仪Synergy H4购自BioTek公司。
1.4实验步骤
接种一定数量的对数生长期细胞于96孔培养板。贴壁生长24小时后，加入不同浓度(10000,3000,1000,300,100,30,10,3,1ng/mL)的药物。药物处理120小时后，用三氯乙酸固定细胞。然后SRB溶液染色；最后加入Tris溶液溶解SRB，酶标仪510nm波长下测定OD值，以下列公式计算细胞生长抑制率：
抑制率＝(OD值对照孔－OD值给药孔)/OD值对照孔×100％
根据各浓度抑制率，用GraphPad Prism 7软件计算半数抑制浓度IC 50。
表1.对HER2阳性肿瘤细胞增殖抑制作用IC 50(ng/mL)
Figure PCTCN2022107479-appb-000062
测试例2：化合物1的体外细胞毒活性筛选
1.1.实验原理及方法
本实验利用CTG检测ATP含量，反映肿瘤细胞的存活情况。首先通过种植不同密度的细胞并培养3天和5天，根据IC 50和最大抑制率确定最终培养条件。然后按照此条件检测毒素分子的杀伤作用。
1.2.细胞株的选择
根据实验目的，选择乳腺癌、NSCLC两种疾病模型，选出SKBR3肿瘤细胞(HER2+，ATCC，货号HTB-30)、MDA-MB-468(HER2-，ATCC，货号HTB-132)和A549(人非小细胞肺癌细胞，ATCC，货号CCL-185)三株细胞用于筛选实验。
1.3.细胞培养条件的确定
1)细胞培养：A549、SK-BR-3和MDA-MB-468细胞分别用含10％FBS(Gibco，10099-141)的Ham’s F-12K(Kaighn’s)培养基(Gibco，21127030)和McCoy's 5A培养基(ThermoFisher，货号16600108)培养及Leibovitz's L-15培养基(ThermoFisher，货号11415-114)进行培养。
2)细胞铺板：将A549用胰酶消化后，用上述培养基终止，计数后分别取4.3×10 5、 7.2×10 5、11.5×10 5个细胞加培养液使终体积均为26ml。在96孔板(康宁，货号3903)第2列到第11列每孔加180ul细胞悬液，使得细胞密度分别为每孔3K、5K、8K。第12列为200ul培养液，剩余孔用PBS填充。SKBR3和MDA-MB-468细胞重复上述操作。平行两份。
2)药物配制：在圆底96孔板(康宁，货号3788)中，用DMSO配制阳性对照艾日布林和本公开化合物储备液。在配药板1的第1列配制2mM(用DMSO将储液稀释10倍)，此后到第10列梯度10倍稀释于DMSO中，第11列为DMSO。配药板2第2列至第11列每孔加入相应培养液95ul，从配药板1的第2列至第11列吸取5ul溶液至配药板2，混匀后，吸取20ul加入铺好的细胞中，继续培养3天和5天。
3)CTG检测(Cell Titer-GloTM，发光细胞生存能力检测，Promega公司)：分别在第3天和第5天取出细胞板，平衡至室温。每孔加入90ul CTG，避光室温反应10min，酶标仪读取发光值并计算IC 50。
1.4.数据结果
表2
Figure PCTCN2022107479-appb-000063
测试例3：化合物1药代动力学测试
1、概述
以
Figure PCTCN2022107479-appb-000064
的比格犬为受试动物，应用LC/MS/MS法测定了比格犬静脉注射给予化合物D-1和艾日布林后不同时刻血浆中的药物浓度。研究本公开化合物在犬体内的药代动力学行为，评价其药动学特征。
2、试验方案
2.1试验药品
化合物D-1和艾日布林
2.2试验动物
比格犬6只，雄性，平均分为2组，由美迪西普亚医药科技(上海)有限公司采购并进行动物给药实验。
2.3药物配制
称取化合物D-1，加5％体积的DMSO，20％PG和20％PEG400使其溶解，然后加入55％生理盐水配制成0.25mg/ml无色澄明溶液。
称取艾日布林，加5％体积的DMSO，20％PG和20％PEG400使其溶解，然后加入55％生理盐水配制成0.25mg/ml无色澄明溶液。
2.4给药
一组犬静脉注射给药化合物D-1，给药剂量均为0.5mg/kg，给药体积均为2ml/kg。
另一组犬静脉注射给药艾日布林，给药剂量均为0.5mg/kg，给药体积均为2ml/kg。
3、操作
犬注射给药化合物D-1，于给药前及给药后5分钟、0.25、0.5、1.0、2.0、4.0、8.0、12.0、24.0小时采血1ml，将收集的血液样本置于EDTA-K2抗凝型采血管中，将收集到的全血放在冰上，1小时内离心分离血浆(离心力2200g，离心10min，2-8℃)。血浆样本在检测前存放于-80℃冰箱内。
犬注射给药艾日布林化合物，于给药前及给药后5分钟、0.25、0.5、1.0、2.0、4.0、8.0、12.0、24.0小时采血1ml，将收集的血液样本置于EDTA-K2抗凝型采血管中，将收集到的全血放在冰上，1小时内离心分离血浆(离心力2200g，离心10min，2-8℃)。血浆样本在检测前存放于-80℃冰箱内。
测定药物注射给药后犬血浆中的待测化合物含量：取给药后各时刻的犬血浆25μl，加入内标溶液喜树碱(中国生物制品检定所)50μl(100ng/mL)和乙腈200μl，涡旋混合5分钟，离心10分钟(3700转/分钟)，血浆样品取上清液3-4μl进行LC/MS/MS(API4000三重四极杆串联质谱仪(No.2)，美国Applied Biosystems公司；Shimadzu LC-30AD超高效液相色谱系统，日本Shimadzu公司)分析。
4、药代动力学参数结果
本公开化合物的药代动力学参数如下表3所示。
表3
Figure PCTCN2022107479-appb-000065
测试例4：ADC-004对人胃癌NCI-N87/16-8裸小鼠皮下移植瘤的疗效
1、实验目的
评价ADC-004对人胃癌NCI-N87/16-8裸小鼠皮下移植瘤的疗效。
2、试验药品
ADC-004，用生理盐水稀释至所需浓度。
3、细胞
人胃癌NCI-N87细胞购自American Type Culture Collection。NCI-N87经T-DM1长期诱导培养对T-DM1耐药，命名为NCI-N87/16-8。细胞用10-cm培养皿培养，培养条件为RPMI 1640培养基(Gibco)中加10％胎牛血清以及青、链霉素，于37℃、含5％CO 2空气的培养箱中培养。一周2-3次传代，当细胞呈指数生长期时，胰酶消化，收集细胞，计数，接种。
4、试验动物
BALB/cJGpt-Foxn1 nu/Gpt小鼠，4周，雌性，购自江苏集萃药康生物科技有限公司。生产许可证号：SCXK(苏)2019-0009；动物合格证号202004958。饲养环境：SPF级。
5、试验步骤
每只裸小鼠皮下接种1×10 7NCI-N87/16-8细胞，待肿瘤生长至100-150mm 3后，根据肿瘤体积和体重将动物分组(D0)。小鼠静脉注射给予0.3和0.6mg/ml的ADC-004，给药体积10mL/kg。每周测2次肿瘤体积，称小鼠体重，记录数据。
6、试验指标
实验指标为考察药物对肿瘤生长的影响，具体指标为T/C％或肿瘤生长抑制率TGI(％)。
每周二次用游标卡尺测量肿瘤直径,肿瘤体积(V)计算公式为：
V＝1/2×a×b 2其中a、b分别表示长、宽。
T/C(％)＝(T-T 0)/(C-C 0)×100其中T、C为实验结束时的肿瘤体积；T 0、C 0为实验开始时的肿瘤体积。
生长抑制率TGI(％)＝100-T/C(％)。
当肿瘤出现消退时，生长抑制率TGI(％)＝100-(T-T 0)/T 0×100
如果肿瘤比起始体积缩小，即T<T 0或C<C 0时，即定义为肿瘤部分消退(PR)；如果肿瘤完全消失，即定义为肿瘤完全消退(CR)。
实验结束、达到实验终点、或溶剂组平均肿瘤体积达到1500mm 3，CO 2麻醉处死动物，随后解剖取瘤并拍照。
7、统计学分析
除非特别说明，二组肿瘤体积之间比较采用双尾Student’s t检验，P<0.05定义为有统计学显著性差异。
8、结果
单次给药后第22天，3mg/k和6mg/kg，ADC-004可以抑制NCI-N87/16-8细胞在裸小鼠皮下移植瘤模型中的生长，抑瘤率分别为46.77％和90.18％(P<0.01 vs PBS control)。荷瘤小鼠对能ADC-004很好耐受，没有体重减轻等症状发生。
9、结论
ADC-004能够有效抑制人胃癌NCI-N87/16-8细胞在裸小鼠皮下移植瘤模型中的生长，荷瘤小鼠对ADC-004能很好耐受。
测试例5：ADC-004对JIMIT-1细胞在裸小鼠皮下移植瘤的疗效
1、试验药品
ADC-004，用PBS稀释至所需浓度。
2、细胞
人乳腺癌JIMIT-1细胞。
4、试验动物
雌性Balb/c nude小鼠
5、试验步骤
BALB/c nude小鼠右侧背部皮下接种JIMT1细胞5×10 5JIMT1细胞，待肿瘤体积达80-100mm 3时，根据肿瘤体积和小鼠体重随机分组，每组6只，分组当天开始给药。HRA00092-C063-004采用PBS稀释至0.6mg/ml静脉注射给药，给药体积为10ml/kg，对照组静脉注射给予相同体积的PBS。
每周二次用游标卡尺测量肿瘤长径和短径，并测量小鼠体重。
肿瘤体积(V)计算公式为：
V＝1/2×a×b 2其中a、b分别表示长、宽。
T/C(％)＝(T-T 0)/(C-C 0)×100其中T、C为实验结束时的肿瘤体积；T 0、C 0为实验开始时的肿瘤体积。
生长抑制率TGI(％)＝100-T/C(％)。
除非特别说明，二组肿瘤体积之间比较采用双尾Student’s T检验，P<0.05定义为有统计学显著性差异。
6、结果
单次给药后第24天，ADC-004可以显著抑制JIMIT-1细胞在裸小鼠皮下移植瘤模型中的生长，抑瘤率为121.3％，其中5只小鼠中的肿瘤都出现了消退(<50mm 3)。荷瘤小鼠对能ADC-004很好耐受，没有体重减轻等症状发生。

Claims (24)

  1. 一种抗体-药物偶联物，其具有式(I)所示的结构：
    Ab-(L-D) k   (I)
    或其药学上可接受的盐或溶剂化物；
    其中，Ab为与HER2的结构域II结合的HER2抗体或其抗原结合片段，
    L为将Ab共价连接于D的连接子，且k为1至20，
    -D如式所示：
    Figure PCTCN2022107479-appb-100001
  2. 根据权利要求1所述的抗体-药物偶联物，其中k选自1至10，可以为整数，也可以为小数。
  3. 根据权利要求1或2所述的抗体-药物偶联物，其中所述连接子包含可裂解肽部分。
  4. 根据权利要求3所述的抗体-药物偶联物，其中所述可裂解肽部分能够由酶裂解，优选能够由组织蛋白酶裂解，进一步的所述组织蛋白酶优选组织蛋白酶B。
  5. 根据权利要求3或4所述的抗体-药物偶联物，其中所述连接子包含氨基酸单元，所述氨基酸单元优选包含由2至7个选自苯丙氨酸、甘氨酸、缬氨酸、赖氨酸、瓜氨酸、丝氨酸、谷氨酸、天冬氨酸的氨基酸构成的肽残基，更优选缬氨酸-瓜氨酸(Val-Cit)、丙氨酸-丙氨酸-天冬酰胺(Ala-Ala-Asn)、甘氨酸-甘氨酸-赖氨酸(Gly-Gly-lys)、缬氨酸-赖氨酸(Val-lys)、缬氨酸-丙氨酸(Val-Ala)、缬氨酸-苯丙氨酸(Val-Phe)或甘氨酸-甘氨酸-苯丙氨酸-甘氨酸(Gly-Gly-Phe-Gly)(SEQ ID NO.7)。
  6. 根据权利要求1或2所述的抗体-药物偶联物，其中所述连接子包含可裂解磺酰胺部分。
  7. 根据权利要求1-3任一项所述的抗体-药物偶联物，其中所述连接子包含可裂解二硫化物部分。
  8. 根据权利要求6或7所述的抗体-药物偶联物，其中所述连接子在还原条件下能够裂解。
  9. 根据权利要求1-8任一项所述的抗体-药物偶联物，其中所述连接子包含连接于D的间隔单元。
  10. 根据权利要求9所述的抗体-药物偶联物，其中所述间隔单元包含对氨基苯甲氧基羰基(pAB)。
  11. 根据权利要求9所述的抗体-药物偶联物，其中所述间隔单元包含
    Figure PCTCN2022107479-appb-100002
    其中，Z 1至Z 4任选自碳原子或氮原子；R 4选自烷基、环烷基、芳基和杂芳基，所述的烷基、环烷基、芳基和杂芳基各自独立地任选被选自烷基、烷氧基、卤素、氨基、氰基、硝基、羟基、羟烷基、环烷基、杂环烷基、芳基和杂芳基中的一个或多个取代基所取代；R 1和R 2各自独立选自氢、C 1-6烷基、卤代烷基或C 3-6环烷基，优选氢；或者，R 1与R 2与其相连接的碳原子一起形成C 3-6环烷基；X选自-O-或-NH-；L选自1-4之间整数；
    Q为V-E，V-E提供了可被位于胞内的糖苷酶切割的糖苷键，E选自-O-、-S-或-NR 3-，R 3选自氢或甲基；进一步地，V选自
    Figure PCTCN2022107479-appb-100003
    其中R 5选自-COOH或CH 2OH。
  12. 根据权利要求1-11任一项所述的抗体-药物偶联物，其中L-D是由下式表示的化学部分：
    -Str-(Pep)-Sp-D，Str是与Ab共价连接的伸展基单元，
    Sp为间隔单元，
    Pep选自氨基酸单元。
  13. 根据权利要求12所述的抗体-药物偶联物，其中Str选自下式表示的化学部分：
    Figure PCTCN2022107479-appb-100004
    其中R 6选自-W-C(O)-、-C(O)-W-C(O)-、-(CH 2CH 2O) p1C(O)-、-(CH 2CH 2O) p1CH 2C(O)-、-(CH 2CH 2O) p1CH 2CH 2C(O)-，其中W选自C 1-8亚烷基、C 1-8亚烷基-环烷基或1至8个原子的直链杂亚烷基，所述杂亚烷基包含1至3个选自N、O或S的杂原子，其中所述的C 1-8亚烷基、C 1-8亚烷基-环烷基和直链杂亚烷基各自独立地任选进一步被选自卤素、羟基、氰基、氨基、烷基、氯代烷基、烷氧基和环烷基的一个或多个取代基所取代；
    L 1选自-NR 7(CH 2CH 2O) p1CH 2CH 2C(O)-、-NR 7(CH 2CH 2O) p1CH 2C(O)-、-S(CH 2) p1C(O)-、-(CH 2) p1C(O)-或化学键，其中p1为1至20的整数，优选化学键；p1为1至20的整数，R 7选自氢原子、烷基、卤代烷基和羟烷基。
  14. 根据权利要求13所述的抗体-药物偶联物，其中R 6选自C 1-6亚烷基C(O)-、-(CH 2-CH 2O) 2C(O)-、-(CH 2-CH 2O) 2CH 2C(O)-、-(CH 2-CH 2O) 2CH 2CH 2C(O)-、-(CH 2-CH 2O) 3C(O)-和-(CH 2-CH 2O) 4C(O)-。
  15. 根据权利要求13或14所述的抗体-药物偶联物，其中连接子L包含：顺丁烯二酰亚胺-(PEG) 2-Val-Cit、顺丁烯二酰亚胺-(PEG) 6-Val-Cit、顺丁烯二酰亚胺-(PEG) 8-Val-Cit、顺丁烯二酰亚胺-(PEG) 4-CH 2CH 2C(O)-Val-lys、顺丁烯二酰亚胺-(CH 2) 5-Val-Cit、顺丁烯二酰亚胺-(CH 2) 5-Val-lys、顺丁烯二酰亚胺-(CH 2) 5-Gly-Gly-Phe-Gly、顺丁烯二酰亚胺-(PEG) 2-Ala-Ala-Asn、顺丁烯二酰亚胺-(PEG) 6-Ala-Ala-Asn、顺丁烯二酰亚胺-(PEG) 8-Ala-Ala-Asn、顺丁烯二酰亚胺-(PEG) 4-三唑-(PEG) 3-磺酰胺、顺丁烯二酰亚胺-(PEG) 2-CH 2CH 2C(O)-Val-lys、顺丁烯二酰亚胺-(PEG) 4-三唑-(PEG) 3-磺酰胺或Mal-(PEG) 4-三唑-(PEG) 3-二硫化物。
  16. 根据权利要求12所述的抗体-药物偶联物，其中Str选自下式表示的化学部分：
    Figure PCTCN2022107479-appb-100005
    其中R 8选自C 1-10亚烷基、C 2-10亚烯基、(C 1-10亚烷基)O-、N(R d)-(C 2-6亚烷基)-N(R d)和N(R d)-(C 2-6亚烷基)；且每个R d独立为H或C 1-C 6烷基。
  17. 根据权利要求1-15任一项所述的抗体-药物偶联物，其由下式表示：
    Figure PCTCN2022107479-appb-100006
    k选自1至10，可以为整数，也可以为小数；p1选自2、4、6或8；p2选自0、1或2；
    Figure PCTCN2022107479-appb-100007
    k选自1至10，可以为整数，也可以为小数；p1选自2、4、6或8；p2选自0、1或2；
    Figure PCTCN2022107479-appb-100008
    k选自1至10，可以为整数，也可以为小数；p1选自2、4、6或8；p2选自0、1或2；
    Figure PCTCN2022107479-appb-100009
    k选自1至10，可以为整数，也可以为小数；p2选自1-6之间整数；
    Figure PCTCN2022107479-appb-100010
    k选自1至10，可以为整数，也可以为小数；p2选自1-6之间整数；
    Figure PCTCN2022107479-appb-100011
    k选自1至10，可以为整数，也可以为小数；p2选自1-6之间整数；
    Ab、D如权利要求1中所定义。
  18. 根据权利要求1-17任一项所述的抗体-药物偶联物，其中所述HER2抗体包含分别在SEQ ID No.1和2中的轻链和重链可变区氨基酸序列，优选地，所述HER2抗体包含分别如SEQ ID No.3和4所示的轻链和重链氨基酸序列。
  19. 根据权利要求1-18任一项所述的抗体-药物偶联物，其由下式表示：
    Figure PCTCN2022107479-appb-100012
    Figure PCTCN2022107479-appb-100013
    Figure PCTCN2022107479-appb-100014
    其中，k选自1至10，可以为整数，也可以为小数。
  20. 根据权利要求1至19中任一项所述的抗体-药物偶联物，其中k选自2.0至2.5、2.5至3.5或3.5至5.0。
  21. 一种权利要求1至20中任一项所述抗体-药物偶联物的同位素取代物，优选地，所述的同位素取代为氘原子取代。
  22. 一种药物组合物，其含有：
    治疗有效量的权利要求1至20任一项所述的抗体-药物偶联物，或者权利要求21所述的同位素取代物，以及
    药学上可接受的载体、稀释剂或赋形剂。
  23. 权利要求1至20任一项所述的抗体-药物偶联物、或权利要求21所述的同位素取代物或权利要求22所述的药物组合物在制备用于治疗或预防肿瘤的药物中的用途。
  24. 根据权利要求23所述的用途，其中所述的肿瘤为与HER2的结构域II表达相关的癌症，所述癌症优选乳腺癌、卵巢癌、宫颈癌、子宫癌、前列腺癌、肾癌、尿道癌、膀胱癌、肝癌、胃癌、子宫内膜癌、唾液腺癌、食道癌、黑色素瘤、神经胶质瘤、神经母细胞瘤、肉瘤、肺癌、结肠癌、直肠癌、结直肠癌、白血病、骨癌、皮肤癌、甲状腺癌、胰腺癌和淋巴瘤。
PCT/CN2022/107479 2021-07-22 2022-07-22 艾日布林衍生物的药物偶联物 Ceased WO2023001300A1 (zh)

Priority Applications (8)

Application Number Priority Date Filing Date Title
EP22845463.3A EP4374879A1 (en) 2021-07-22 2022-07-22 Drug conjugate of eribulin derivative
KR1020247004483A KR20240037267A (ko) 2021-07-22 2022-07-22 에리불린 유도체의 약물 접합체
JP2024502528A JP2024525854A (ja) 2021-07-22 2022-07-22 エリブリン誘導体の薬物複合体
CN202280041358.1A CN117460540A (zh) 2021-07-22 2022-07-22 艾日布林衍生物的药物偶联物
CA3225975A CA3225975A1 (en) 2021-07-22 2022-07-22 Drug conjugate of eribulin derivative
US18/290,721 US20240382607A1 (en) 2021-07-22 2022-07-22 Drug conjugate of eribulin derivative
MX2024000893A MX2024000893A (es) 2021-07-22 2022-07-22 Farmaco conjugado de un derivado de eribulina.
AU2022316425A AU2022316425A1 (en) 2021-07-22 2022-07-22 Drug conjugate of eribulin derivative

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202110830783.6 2021-07-22
CN202110830783 2021-07-22

Publications (1)

Publication Number Publication Date
WO2023001300A1 true WO2023001300A1 (zh) 2023-01-26

Family

ID=84978957

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2022/107479 Ceased WO2023001300A1 (zh) 2021-07-22 2022-07-22 艾日布林衍生物的药物偶联物

Country Status (10)

Country Link
US (1) US20240382607A1 (zh)
EP (1) EP4374879A1 (zh)
JP (1) JP2024525854A (zh)
KR (1) KR20240037267A (zh)
CN (1) CN117460540A (zh)
AU (1) AU2022316425A1 (zh)
CA (1) CA3225975A1 (zh)
MX (1) MX2024000893A (zh)
TW (1) TW202310878A (zh)
WO (1) WO2023001300A1 (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024109840A1 (zh) * 2022-11-22 2024-05-30 康诺亚生物医药科技（成都）有限公司 稠环类化合物及其偶联物和用途
WO2025176180A1 (zh) * 2024-02-23 2025-08-28 江苏恒瑞医药股份有限公司 艾日布林衍生物药物偶联物用于治疗肿瘤的用途

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
CN1312804A (zh) * 1998-06-17 2001-09-12 卫材株式会社 大环类似物及其使用和制备的方法
US20050238649A1 (en) 2003-11-06 2005-10-27 Seattle Genetics, Inc. Monomethylvaline compounds capable of conjugation to ligands
WO2006033700A2 (en) 2004-07-22 2006-03-30 Genentech, Inc. Her2 antibody composition
WO2013106717A1 (en) 2012-01-13 2013-07-18 The General Hospital Corporation Anesthetic compounds and related methods of use
WO2017151979A1 (en) 2016-03-02 2017-09-08 Eisai Inc. Eribulin-based antibody-drug conjugates and methods of use
WO2021090062A1 (en) * 2019-11-07 2021-05-14 Eisai R&D Management Co., Ltd. Anti-mesothelin eribulin antibody-drug conjugates and methods of use
WO2021132166A1 (ja) * 2019-12-23 2021-07-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 エリブリンをベースとする抗体－薬物コンジュゲートの製造方法
WO2022022508A1 (zh) * 2020-07-27 2022-02-03 上海拓界生物医药科技有限公司 抗cd79b抗体药物偶联物、其制备方法及其医药用途

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
CN1312804A (zh) * 1998-06-17 2001-09-12 卫材株式会社 大环类似物及其使用和制备的方法
US20050238649A1 (en) 2003-11-06 2005-10-27 Seattle Genetics, Inc. Monomethylvaline compounds capable of conjugation to ligands
WO2006033700A2 (en) 2004-07-22 2006-03-30 Genentech, Inc. Her2 antibody composition
WO2013106717A1 (en) 2012-01-13 2013-07-18 The General Hospital Corporation Anesthetic compounds and related methods of use
WO2017151979A1 (en) 2016-03-02 2017-09-08 Eisai Inc. Eribulin-based antibody-drug conjugates and methods of use
CN108883198A (zh) * 2016-03-02 2018-11-23 卫材研究发展管理有限公司 基于艾日布林的抗体-药物偶联物和使用方法
WO2021090062A1 (en) * 2019-11-07 2021-05-14 Eisai R&D Management Co., Ltd. Anti-mesothelin eribulin antibody-drug conjugates and methods of use
WO2021132166A1 (ja) * 2019-12-23 2021-07-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 エリブリンをベースとする抗体－薬物コンジュゲートの製造方法
WO2022022508A1 (zh) * 2020-07-27 2022-02-03 上海拓界生物医药科技有限公司 抗cd79b抗体药物偶联物、其制备方法及其医药用途

Non-Patent Citations (23)

* Cited by examiner, † Cited by third party
Title
"Methods in Molecular Biology", vol. 66, 1996, article "Epitope Mapping Protocols"
ALFTHAN ET AL., PROTEIN ENG, vol. 8, 1995, pages 725 - 731
AL-LAZIKANI ET AL., JMB, vol. 273, 1997, pages 927 - 948
CHARI ET AL., CANCER RESEARCH, vol. 52, 1992, pages 127 - 131
CHENG XIN, LI JING, TANAKA KEIGO, MAJUMDER UTPAL, MILINICHIK ANDREW Z., VERDI ARIELLE C., MADDAGE CHRISTOPHER J., RYBINSKI KATHERI: "MORAb-202, an Antibody–Drug Conjugate Utilizing Humanized Anti-human FRα Farletuzumab and the Microtubule-targeting Agent Eribulin, has Potent Antitumor Activity", MOLECULAR CANCER THERAPEUTICS, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 17, no. 12, 1 December 2018 (2018-12-01), US , pages 2665 - 2675, XP055831595, ISSN: 1535-7163, DOI: 10.1158/1535-7163.MCT-17-1215 *
CHOI ET AL., EUR. J. IMMUNOL., vol. 31, 2001, pages 94 - 106
FRANKLIN ET AL., CANCER CELL, vol. 5, 2004, pages 317 - 328
HOLLIGER ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 6444 - 6448
HU ET AL., CANCER RES, vol. 56, 1996, pages 3055 - 3061
HUSTON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 85, 1988, pages 5879 - 5883
IMMUNOGLOBULIN JOURNAL, 2001, ISBN: 012441351
J. BIOL. CHEM, vol. 243, 1968, pages 3558
JONES ET AL., NATURE, vol. 321, 1986, pages 522
KABAT E.A. ET AL.: "NIH Publication 91-3242", 1991, article "Sequences of proteins of immunological interest"
KABAT ET AL.: "Sequences of Proteins of Immunological Interest", 1991, PUBLIC HEALTH SERVICE, NATIONAL INSTITUTES OF HEALTH
KIPRIYANOV, J. MOL. BIOL., vol. 293, 1999, pages 41 - 56
LEFRANC M.P., IMMUNOLOGIST, vol. 7, 1999, pages 132 - 136
LEFRANC, M.P. ET AL., DEV. COMP. IMMUNOL., vol. 27, 2003, pages 55 - 77
QUEEN ET AL., PROC. NATL. ACAD. SCI. USA, vol. 88, 1991, pages 2869
RIECHMANN ET AL., NATURE, vol. 332, 1988, pages 323 - 327
ROOVERS ET AL., CANCER IMMUNOL., 2001
VERHOEYEN ET AL., SCIENCE, vol. 242, 1988, pages 1534 - 426
WARD ET AL., NATURE, vol. 341, 1989, pages 544 - 546

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024109840A1 (zh) * 2022-11-22 2024-05-30 康诺亚生物医药科技（成都）有限公司 稠环类化合物及其偶联物和用途
WO2025176180A1 (zh) * 2024-02-23 2025-08-28 江苏恒瑞医药股份有限公司 艾日布林衍生物药物偶联物用于治疗肿瘤的用途

Also Published As

Publication number Publication date
JP2024525854A (ja) 2024-07-12
CN117460540A (zh) 2024-01-26
KR20240037267A (ko) 2024-03-21
TW202310878A (zh) 2023-03-16
CA3225975A1 (en) 2023-01-26
AU2022316425A1 (en) 2024-02-01
US20240382607A1 (en) 2024-11-21
MX2024000893A (es) 2024-02-06
EP4374879A1 (en) 2024-05-29

Similar Documents

Publication Publication Date Title
US12377163B2 (en) Anti-B7H3 antibody-exatecan analog conjugate and medicinal use thereof
TWI891714B (zh) 抗trop-2抗體-依喜替康類似物偶聯物及其醫藥用途
WO2021052402A1 (zh) 一种喜树碱衍生物及其偶联物
TW202214306A (zh) 抗ｃｄ７９ｂ抗體藥物偶聯物、其製備方法及其醫藥用途
WO2021190586A1 (zh) B7h3抗体-依喜替康类似物偶联物及其医药用途
WO2021115426A1 (zh) 抗密蛋白抗体药物偶联物及其医药用途
CN115298186B (zh) 抗psma抗体-依喜替康类似物偶联物及其医药用途
CN113121639B (zh) 澳瑞他汀类似物及其偶联物、其制备方法及其应用
WO2022262789A1 (zh) 一种抗肿瘤化合物及其应用
TWI887316B (zh) 抗ｃｅａ抗體-依喜替康類似物偶聯物及其醫藥用途
WO2023001300A1 (zh) 艾日布林衍生物的药物偶联物
CN115845080A (zh) 艾日布林衍生物-抗叶酸受体抗体偶联物
HK40082496A (zh) 抗psma抗体-依喜替康类似物偶联物及其医药用途
HK40082496B (zh) 抗psma抗体-依喜替康类似物偶联物及其医药用途
HK40074739B (zh) 抗cea抗体-依喜替康类似物偶联物及其医药用途
HK40076788B (zh) 抗trop-2抗体-依喜替康类似物偶联物及其医药用途
HK40074739A (zh) 抗cea抗体-依喜替康类似物偶联物及其医药用途
HK40076788A (zh) 抗trop-2抗体-依喜替康类似物偶联物及其医药用途
HK40047594A (zh) 抗b7h3抗体-依喜替康类似物偶联物及其医药用途

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22845463

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 202280041358.1

Country of ref document: CN

ENP Entry into the national phase

Ref document number: 3225975

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 202393576

Country of ref document: EA

ENP Entry into the national phase

Ref document number: 2024502528

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: MX/A/2024/000893

Country of ref document: MX

Ref document number: 2022316425

Country of ref document: AU

Ref document number: AU2022316425

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 18290721

Country of ref document: US

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112024000957

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2022316425

Country of ref document: AU

Date of ref document: 20220722

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20247004483

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020247004483

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 202427011500

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2022845463

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2022845463

Country of ref document: EP

Effective date: 20240222

WWE Wipo information: entry into national phase

Ref document number: 11202400113Y

Country of ref document: SG

ENP Entry into the national phase

Ref document number: 112024000957

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20240117